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The following abbreviations were used in this work:
secs seconds,
mins minutes,
hrs hours.
1 litre(s).
ml(s) millilitre(s).
ul microlitre(s).
g gramme(s).
mg(s) railligramme( s).
ug microgrammes,
ng nanogramme(s ).
M molar.
ulM millimolar.
uM micromolar,
bp base pair(s).
ko kilobase pairs,
m.wt. molecular weight.
C degrees celcius.
V volts.
W watts.
uCi microCurie.
G centrifugal force equal to gravitational accelaration,
cm centimetre,
mm millimetre.
Tris tris (hydroxymethyl) aminomethane.
EDTA ethylene diamine tetra-acetic acid.
BSH beta mercaptoethanol.
DTT di-thiotreitol.
X-gal 5-bromo, 4-chloro, 3~indolyl B-D galactopyranoside. 
PMSF phenyl.aethylsulphonyl Fluoride. .
ATP adenosine triphosphate.
CTP cytosine triphosphate.
GTP guanosine triphosphate.
TTP thymidine triphosphate.
DNA deoxyribonucleic acid.
cDNA complementary DNA.
RNA ribonucleic acid.
tRNA transfer RNA.
RNAse ribonuclease.
kan kanamycin.
amp ampicillin.
SDS sodium dodecyl sulphate.
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This work describes the design, cloning and 
expression of a synthetic gene encoding a human peptide 
hormone, (3-urogastrone-epidermal growth factor. This is a 53 
amino-acid polypeptide incorporating two separate biological 
activities: i) It inhibits the secretion of gastric HCl and 
ii) It stimulates growth of epidermal cells both iji vivo and 
in cell culture. Preliminary studies using £-urogastrone 
isolated from human urine have indicated that the peptide 
may have potential medical applications in the treatment of 
gastric ulcers. However its isolation and purification from 
this source is extremely inefficient and time consuming.
Bacterial expression was therefore investigated as a 
viable alternative source of the peptide. In addition, total 
gene synthesis was examined as a suitable alternative to the 
isolation of the gene from natural sources. Various 
theoretical and practical concepts of gene design are 
discussed. The preliminary expression of f$-urogastrone in 
E .coli was carried out, using regulatory regions derived 
from the host tryptophan (trp), biosynthetic operon. 
Subsequently a series of vectors were designed to enable 
expression in an alternative host, B .subtilis. The 
expression system was incorporated on a dual-replicon 
plasmid allowing selectable propagation and a study of 
expression in both B .subtilis and in E .coli. Transcription 
was initiated from an early promoter derived from a 
B .subtilis phage and fully characterised here. Translation 
was achieved using synthetic ribosome binding sites.
Subsequently, the use of site-directed mutagenesis 
permitted the development of this system to enable the 
future expression of additional genes.
CHAPTER 1
INTRODUCTION
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1.1 Foreword
Genome organisation and the regulation of gene 
expression in living organisms has been subject in the past 
ten years, to one of the most intense investigations seen in 
biological science. The primary reason for this intense 
activity has been the development of an entirely new 
technology in molecular biology which has enabled 
investigators to isolate, manipulate and ultimately 
determine the nucleotide sequence of large, specifically 
selected regions of DNA. Using plasmids as vectors, 
particular genes can be maintained for study and 
subsequently re-introduced to either their original host or 
to a different organism.
The vast majority of experiments involving this 
technology has been performed in the bacterium Escherichia 
coli for two main reasons. Firstly it is better 
characterised biochemically and genetically than any other 
organism, providing many immediate topics for investigation 
and secondly it has proved the most suitable host for the 
preparation and manipulation of chromosomal and plasmid DNA. 
It is therefore not surprising that the greatest degree of 
knowledge has been attained concerning the structure and 
function of the E .coli chromosome as well as those of its 
phages. This has in turn enabled much of the classical 
biochemical and genetical analysis of E .coli to be elegantly 
complemented at the molecular level.
However the molecular genetics of many other micro­
organisms especially Bacillus subtilis and yeast have also 
been investigated using these techniques and there is an 
increasing understanding of the mechanisms they employ in 
the regulation of gene expression. Similarly a large number 
of mammalian genes have been isolated and sequenced giving a 
preliminary understanding of the organisation of the
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eukaryotic genome. Evolutionary considerations of genome 
structure have been greatly enhanced by the comparison of 
DNA sequence both in closely related and widely divergent 
organisms and with sequence analysis of transposable 
elements and introns has come substantial insight to the 
fluidity of bacterial and eukaryotic genomes.
In short, the vast accumulation of sequence data has 
permitted an understanding of both the coding sequence and 
of specific regulatory regions of DNA involved in such 
processes as genome replication, recombination, 
transcription and translation at a level of definition not 
previously attainable.
Perhaps the most exciting aspect of this revelation 
in the control of gene expression lies in the prospect of 
specific alteration of the DNA sequence. Whereas in the past 
geneticists have used the natural occurence of, mutation or 
non-specific mutagens to study biological systems, the 
potential now exists to study the effects on cellular 
processes of DNA mutations specifically introduced at any 
given point in the sequence. Furthermore it is becoming a 
realistic possibility to specifically insert, delete or 
combine particular fragments of DNA known to be involved in 
the control of gene expression, both in an effort to better 
resolve the function of regulatory regions and to bring 
about the production of heterologous peptides in any given 
host. Crucial to this kind of investigation has been the use 
of chemically synthesised oligomers of DNA. A process not 
particularly new in itself but whose recent rapid 
improvements in speed, accuracy and efficiency have turned 
it into one of the most important tools available to the 
molecular biologist.
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Using the genetic code and having determined the 
amino-acid sequence of a particular peptide it is now 
possible to design and build DNA sequences capable of 
encoding that peptide. Furthermore by considering the 
regulation of gene expression at the primary sequence level 
for the chosen host and speculating upon the possible role 
of DNA and RNA secondary structure it should also be 
possible to design putative regulatory elements of DNA for 
the gene in question and study their function in the 
organism.
The work in this thesis involves many of the current 
rapid DNA handling techniques and uses specifically 
designed, chemically synthesised sequences of DNA. Both 
coding and regulatory sequences have been designed to 
examine the production of a human hormone, |3-urogastrone 
both in E .coli and in Bacillus subtilis.
1.2 Reasons for cloning the (3-urogastrone gene.
The cloning in bacteria of human genes has not only 
been desirable to examine the organisation of the human
genome. It has also enabled the evaluation of the possible
therapeutic potential of several hormones and enzymes which 
previously could not be isolated either in sufficient 
quantity for study or without extreme difficulty and cost. 
Obvious examples at present are human insulin (1), human 
growth hormone (2), and interferon (3) which have been 
subject to great commercial interest and which can now be 
synthesised and isolated from bacteria in far greater 
quantities than from pre-existing sources.
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(3-urogastrone similarly has considerable therapeutic 
potential and has emerged as an important regulatory 
molecule with much current interest being directed into its 
structure and function (4). The (3 form is the more abundant 
of the two forms of urogastrone detected by sensitive 
radio-immunoassay in humans. Found predominantly in the 
salivary glands, duodenum and urine (5,6,7), it is a 53 
amino-acid single peptide chain of mwt 6.2 kDal 
incorporating three disulphide bonds (8). The y form lacks 
the C-terminal arginine residue but is otherwise identical 
(8) and shows very similar biological activities.
(3-urogastrone is strikingly homologous in structure 
and function to mouse epidermal growth factor (EGF) isolated 
from the submaxillary gland (9). Both peptides inhibit 
gastric acid secretion (10,11) and will similarly stimulate 
growth of epidermal cells both in vivo (11,8) and in vitro 
(12). The amino-acid sequence bears such close homology to 
mouse EGF and to the bulk amino-acid composition obtained 
for human EGF that it seems likely that (3-urogastrone and 
EGF are one and the same molecule (8). Residues in the 
C-terminus of the peptide are crucial to the EGF activity as 
removal of the terminal six residues by limited proteolysis 
reduces this activity ten fold whilst not affecting the 
inhibition of gastric acid secretion (13).
Obviously a molecule with activity to temporarily 
reduce the secretion of acid in the stomach has potential 
medical applications in the treatment of peptic ulcers, as 
gastric HCl is an antagonist to the healing of ulcerated 
tissue. Furthermore the growth factor activity of 
(3-urogastrone may prove to be useful in actually increasing 
the rate of healing of the lesion. The therapeutic potential 
of the peptide has indeed shown promising results in human 
trials which have been carried out using urine derived 
material (14). However it seems likely that much larger
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quantities of (3-urogastrone will be required not only if its 
clinical applications are to be pursued, but also for a 
substantial basic research effort into its tertiary 
structure and its biological activities, with particular 
emphasis on its mechanism of action as a growth factor.
Epidermal growth factor and its cellular receptor 
have, along with other human growth factors become the 
subject of intense interest to tumour biologists. This is 
due to the interaction of the receptor with known tumour 
promoters such as phorbol esters (15) and very recently with 
their observed structural homology and proposed functional 
significance with the products of retroviral oncogenes (16) 
and retrovirus transformed cells (17). Obviously this facet 
of the biological function of EGF is of extreme importance 
and may be of fundamental relevance to the molecular biology 
of cancer. It is also an aspect of (3-urogastrone action 
which must be closely investigated with respect to its 
potential clinical applications.
Its conventional isolation however, in yields of less 
than lmg per 10001 of urine (8) is clearly an impractical 
and unattractive source of material for study. This has led 
to the investigations into the possibility of the molecular 
cloning of its gene.
Molecular cloning of the genes for other human 
peptides has recently yielded sufficient material for 
satisfactory studies to be carried out where conventional 
methods have proved too arduous. It seems reasonable to 
imagine that in this case the same approach could lead to 
sufficient quantities of (3-urogastrone becoming available.
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1.3 Possible gene cloning strategies
In order to isolate a DNA sequence encoding a 
particular peptide it is necessary to have both a source of 
appropriate DNA or RNA and a suitable selection procedure, 
either for the cloned gene or for the product it encodes. In 
the case of a eukaryotic gene and in particular a human gene 
there are usually considerable problems associated with 
these requirements.
Direct selection of cloned DNA sequences expressing 
human peptides is usually most easily carried out using 
specific radiolabelled antisera, as biological assay if at 
all possible is generally complex and time consuming. Since 
in this case neither an antiserum nor any form of workable 
biological assay was available at the time, the alternative 
remained to isolate |3-urogastrone encoding sequences by 
means of hybridisation to a homologous DNA sequence. Since 
no natural DNA fragment known to be homologous to the 
p-urogastrone gene was available to use as a "probe" this 
would require the synthesis of an oligomer of DNA derived 
from the known amino-acid sequence of the peptide.This could 
then be used either to directly probe a human genomic or 
cDNA library or as a primer to specifically initiate 
synthesis of a cDNA on the desired messenger RNA.
The drawbacks to these techniques are numerous. 
Firstly, due to the degeneracy of the genetic code it is 
usually impossible to find a region of the peptide from 
which to deduce a probe sequence long enough to be 
sufficiently stringent yet with only one possible coding 
sequence. The best that can usually be attained is to 
determine a region containing one or more amino acids 
encoded by only one or two possible codons, such as 
tryptophan or methionine. In this event only very few probes 
need be constructed to cover all possible DNA coding
-18-
sequences. In the case of (3-urogastrone the most appropriate 
region is shown below.
residues (47) LEU.......  -LYS-TRP-TRP-GLU- LEU (52)
AAA TGG TGG GAA TTA
G G C G
C 
T
  12 mer ----
 14 m e r   ------------
Four possible DNA sequences can encode this 
tetrapeptide from reidues 48 to 51. Further elongation of 
the 12'mer would necessitate building eight 14'mers and so 
the disproportionate rise in workload during the screening 
process becomes evident. Hybridisation of such numbers of 
short sequences to a genomic library of human DNA is 
extremely impractical as sequences identical and closely 
homologous to these will occur quite frequently. This would 
probably require a great deal of analysis with a high 
background due to the difficulties in achieving optimum 
stringency. Furthermore, the isolation of eukaryote genomic 
DNA for genes intended to be expressed in prokaryotes is 
usually undesirable due to the presence of introns in most 
eukaryote genes which are not correctly processed in 
bacteria (18). Finally there is some question over the 
representative nature of gene libraries and the stability of 
inserts of particular size or structure (19). It is possible 
that some sequences are present in low abundance or not at 
all.
Base TTA
variations. C G
C
T
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The more attractive proposition is to selectively 
enrich for clones of the desired sequence. This is achieved 
by specifically probing or priming cDNA derived from the 
mRNA of cells known to produce the protein in question.
Since there were no appropriate cell lines available for the 
isolation of (3-urogastrone mRNA this would necessitate the 
extraction of the RNA from fresh tissue. In the case of a 
human protein however, tissue availability is obviously, 
with few exceptions such as the placenta, a severe 
restriction. In addition 3-urogastrone is produced in the 
cells of the small intestine which even when available 
following surgical removal present considerable obstacles to 
the extraction of mRNA, since this tissue is tough, 
difficult to denature quickly and abundant in nucleases.
This necessitates prolonged and difficult work at low 
temperatures.
Consideration of these biological and technical 
difficulties coupled with the developments occuring in the 
field of gene synthesis and the various other advantages of 
a specifically designed gene, led to the serious 
consideration of total gene synthesis as a realistic 
alternative to the isolation of the coding sequence from 
natural sources. Previously, oligonucleotides of synthetic 
DNA have been used in gene synthesis (20) but recent 
improvements in the methodology of chemical synthesis and 
HPLC purification (21) have vastly increased the rate and 
accuracy of oligonucleotide synthesis and purification. This 
enabled the 23 oligomers required for the assembly of the 
3-urogastrone gene, which ranged from 12 to 20 bases in 
length, to be synthesised within a few weeks.
2115 23
2012 15
i 8  v— Tb10 13
118 . 2 1 . 2 3 . 2 2 .  2 0 .1 814 .1 2  .1 3  .1 5  . 1 78  .1 15 . 732 1
8 ’  10 17 '1 5  ’  13 '1 2  ’  14 16 *1 8  ’ 2 0  ’ 22  ’ 23  ’  21 ’  18
10
V■v V vnr Y V■Y V 1027 3 18 5 411
17 15 ’ 13 12 14 ’  1? T 18 20  T22 ’ 23  ’ 21 '1 8
Xba I 
B«m H I 
18 .2 1  .2 3p u  .ia .w <■
■VZi » »•»« »12 14 '  16 ’  18 2 0  ’  22
Hind III 
Xba I
2 '  4 •  8  10
Figure 1. Strategy of gene assembly.
Schematic representation of the stages of gene assembly and 
structure of the intermediate sub-assemblies.
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1.4 Design of the synthetic gene
1.4.1 Codon choice
Obviously the degeneracy of the genetic code permits 
some degree of flexibility in the choice of nucleotide 
sequence designed to encode a given peptide. This allows 
various biological and technical parameters to be considered 
and compromised upon, in designing the optimum sequence.
E .coli like most organisms for which DNA sequence 
data are available displays a preference for the use of 
particular codons in the coding sequence of its genome (22). 
This reflects the abundance of the corresponding charged 
tRNA molecules in the cytoplasm (23). The effect of this 
bias on the efficiency of translation is still unclear but 
it would seem prudent to incorporate where possible within a 
synthetic gene designed to be expressed in E .coli, the most 
frequently used codons of the host or to at least avoid the 
most infrequently used ones. This minimises the possibility 
of encountering any translational limitation which may be 
imposed by the cell. This may be especially relevent to a 
plasmid borne gene present in multiple copies and expressed 
at high levels. Codon preference in B .subtilis is less well 
documented due to the small number of genes yet sequenced. 
However it appears that there is no gross dissimilarity of 
codon choice with that of E .coli involving the codons used 
in the synthetic 0-urogastrone gene (24). Very recently it 
has been suggested that codon bias may be less significant 
in B .subtilis than in E .coli (25).
1.4.2 Considerations as to the method of gene assembly
I considered that the assembly of the gene would be 
most easily carried out by means of sequential 
hybridisation-ligation reactions, as illustrated in Figure 
1, with purification of correctly assembled intermediates 
for subsequent assemblies. This minimises the risk of
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undesired hybridisations between non-adjacent fragments 
which could occur if large numbers of oligomers were mixed. 
Obviously the greatest yield of each correctly ligated 
sub-assembly will be achieved by optimising the ratio of 
correctly to incorrectly hybridised oligomers. Avoidance of 
incorrectly aligned fragments is best achieved using maximum 
overlap between oligomers and minimum incorporation of 
repeated or palindromic sequences. This is obviously most 
relevant to the initial stages of gene assembly since the 
purification of intermediates lessens the need for stringent 
avoidance of potentially homologous regions between distant 
fragments, as these will have been incorporated into higher 
molecular weight structures by the later stages of asembly. 
In order to avoid undesired homology between oligomers, 
computer programmes were employed which using free energies 
of base pairing (26) predict the relative stability of 
correct and undesired hybridisations between specific 
fragments.
1.4.3 Inclusion of specific restriction endonuclease sites 
Using these two major criteria to design a framework 
sequence for the gene it is then extremely useful to 
incorporate where possible, specific restriction 
endonuclease sites both terminally and internally. This 
facilitates not only cloning and sequencing of the completed 
gene but analysis of assembly intermediates and following 
expression permits the replacement of particular fragments 
by alternative sequences. This in turn allows the simple 
alteration of the structure of the gene or the peptide.
-22-
1.5 Bacterial expression of the synthetic gene
1.5.1 Levels of regulation
The expression in a bacterium of any plasmid-borne 
gene whether natural or synthetic in origin, is regulated at 
several levels by the host cell. The efficiency of 
transcription and translation of the gene, the stability and 
the copy number of the plasmid and the effects of cellular 
nucleases and proteases all exert a major influence upon the 
levels of the particular mRNA and peptide within the cell. 
Whereas the mechanisms and pathways of specific nucleic acid 
and protein degradation are only beginning to be elucidated 
(27,28) the mode of regulation of gene expression has now
been examined in great detail. Specifically, the role of the
primary structure of DNA on the regulation of mRNA and 
protein synthesis has been sufficiently elucidated to enable 
the isolation of sequences of DNA and RNA which regulate 
transcription and translation both positively and 
negatively. These sequences can then be combined and 
modified to form expression systems capable of synthesising 
high levels of foreign protein in the bacterial cell (29). 
Particular sequences of DNA are now known to regulate 
transcription either by direct interaction with RNA 
polymerase (30) or with repressor proteins (31). Similarly 
regions of mRNA sequence have been shown to interact 
specifically with ribosomal RNA in the regulation of 
translation (32). The formation of stable DNA and RNA 
secondary structures have also been shown to be very 
important in the control of both transcription and 
translation (33,34).
1.5.2 Choice of expression system in E .coli
One of the best characterised regulatory regions of 
the E .coli genome is that of the tryptophan (trp) 
biosynthetic operon. The sequence of the entire operon has 
now been determined and the composition and function of the
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transcription promoter, operator and attenuator have been 
extensively studied and understood (35). This has enabled 
their use to express foreign proteins in E .coli (3,36). This 
has also been the case with the regulatory regions of the 
E .coli lactose (lac) operon (37). In addition, a series of 
plasmids were available during the course of this work which 
contained derivatives of the trp promoter region and of the 
translation intiation point of the first gene in the operon, 
trpE. Genes may be easily cloned into these vectors and 
their expression induced in E .coli (38,39). Gene expression 
from the trp promoter can be simply induced by the presence 
of 3 ^-indole acrylic acid which operates by a three-fold 
effect: (i) In inhibiting the binding of the repressor 
protein to the trp operater, (ii) in inhibiting the charging 
of tRNA^rP thereby overcoming attenuation and (iii) by 
inhibition of the action of tryptophan synthetase, thus 
further reducing cellular levels of tryptophan. Using these 
plasmids proteins may be expressed in the mature form or 
fused to the initial residues of the trpE gene product, 
anthranilate synthetase. This seemed therefore a suitable 
means by which to express the synthetic gene in E .coli and 
the sequence was therefore designed to be inserted into 
these plasmids.
1.5.3 Peptide fusions
Protein fusions, in which DNA sequences of two host 
peptides or of host and foreign peptides are linked have 
been widely applied in the study of gene expression in 
prokaryotes (37,40,47). They have also proved useful in the 
examination of protein secretion and in the stabilisation of 
foreign peptides (20,41). Prior to rapid gene synthesis and 
site-directed mutagenesis the expression of fused gene 
products has often avoided the necessity for extremely 
difficult and time-consuming plasmid manipulations and has 
permitted more simple detection and assay of the expressed
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Figure 2. The synthetic <3-urogastrone gene.
The synthetic £-urogastrone gene, showing the nucleotide 
and amino-acid sequence, the individual oligonucleotides 
and the six base-pair restriction enzyme sites.
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proteins. To facilitate studies upon the efficiency of gene 
expression and upon the stability of the p-urogastrone 
peptide, the synthetic gene was therefore designed to be 
capable of expression either as a "mature" peptide or as a 
peptide fusion. The design enabled fusion to the initial 
residues of the trpE gene product, anthranilate synthetase 
in the expression vector. Since 0-urogastrone is known to be 
resistant to internal cleavage by trypsin, a linker region 
was designed which incorporated a trypsin labile site 
immediately preceding the first residue of the peptide. 
Subsequent cleavage of the fusion at this point yields the 
mature peptide. Similarly, restriction sites were included 
close to the C-terminal coding region of the gene to enable 
potential fusions to peptides such as 0-Galactosidase. This 
provides a more simple assay (42) and easier screening of 
recombinants using the chromogenic substrate X-gal which is 
cleaved by p-galactosidase releasing a blue indolyl 
derivative.
The resultant gene was a 174 base-pair duplex flanked 
by unique Hind III and Bam HI restriction endonuclease 
sites. It encoded the 53 amino acids of p-urogastrone 
immediately followed by a TAA translation termination codon 
and preceded by the trypsin labile dipeptide LYS-LYS. This 
is depicted in Figure 2. The Hind III site allowed ligation 
to the Hind III site within the modified trpE gene, the 
unique Bam HI site facilitated the addition, removal or 
replacement of sequences of DNA or RNA downstream of the 
gene and a unique Eco RI site permitted the removal of DNA 
prior to the first nucleotide of the coding sequence. This 
enabled the expression of the mature peptide using specific 
linkers incorporating sequences known to function as 
ribosome binding sites. The synthetic gene thereby not only 
avoided many technical obstacles normally encountered during 
the cloning of a human gene but provided the potential 
opportunity for considerable studies upon the regulation of
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the expression of a human peptide in heterologous hosts.
1.6 Design of a gene expression system in B .subtilis
1.6.1 Bacilli as hosts for foreign gene expression.
Since E .coli is the best genetically and 
biochemically characterised prokaryotic organism, it is not 
surprising that most experiments to date involving gene 
cloning have been carried out using specially constructed 
strains of E .coli as the host and derivatives of its natural 
plasmids and phages as vectors for cloned genes. The most 
widely used systems employ E .coli K12 with ColEl derived 
plasmids such as pBR322 (43a and b) and derivatives of phage 
X and M13 (44,45,46). In such systems well characterised 
regulatory regions of the E .coli chromosome such as those of 
the tryptophan and lactose operons as well as X Pi and Pr 
(45) have been employed in the expression of plasmid borne 
genes. In ever the less, there are a number of good reasons for 
the pursuit of efficient and versatile plasmids and gene 
expression systems in other prokaryote hosts, especially the 
bacilli and of Bacillus subtilis in particular.
Primarily, being the best biochemically and 
genetically studied gram-positive prokaryote Bacillus 
subtilis provides an obvious opportunity for comparisons of 
genome organisation and regulation with that of E .coli as 
well as the study of processes such as sporulation which 
cannot be examined using E .coli.
In addition, bacilli have for many years been very 
important organisms in industrial fermentation, in the 
production of amino acids, vitamins and enzymes. Since many 
biosynthetic genes of E .coli have already been isolated 
using molecular cloning it is quite possible that the 
cloning and manipulation of tightly regulated genes may also
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be of use in the study of these processes in bacilli and 
could lead to improvements in the overall yields of 
fermentations. Indeed considering the increasing industrial 
interest in the use of micro-organisms for the production of 
enzymes and hormones in general, B .subtilis may emerge due 
to its non-pathogenicity and ability to secrete large 
quantities of particular proteins (48), as an altogether 
more preferable organism to E .coli for the large scale 
production of genetically engineered proteins. Such 
industrial applications of molecular cloning in B .subtilis 
depend on a rapid increase in the understanding of the 
molecular genetics of the organism to the level of that 
currently determined for E .coli.
However, no such ubiquitous systems as those based 
upon the E .coli trp or lac promoters, exist as yet to study 
gene expression in B .subtilis, due to the fact that far 
fewer groups have applied molecular cloning to the study of 
this organism than to that of E .coli. This in due in part to 
the better biochemical and genetical understanding of E .coli 
than of B .subtilis, and also to the fact that E .coli has 
proven to be a convenient and versatile host for many gene 
manipulation experiments whilst B .subtilis is a more 
difficult organism to manipulate using recombinant DNA 
technology. In addition, intracellular proteolysis of 
foreign peptides has often been a problem in B .subtilis 
(49). This can be at least partially overcome however by the 
use of protease deficient strains although these were not 
available during the course of this work. Development of 
efficient protein secretion systems for foreign peptides 
might also overcome this problem and reduce proteolysis of 
peptides to a degree below that observed in E .coli. Very 
recently however the development of molecular cloning and 
gene expression systems for use in B .subtilis and other 
bacilli has become a subject of increasing interest.
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A number of groups have now developed plasmids for 
the cloning of genes in B.subtilis (50,51,52) and have used
phage (53) and chromosomal (54) promoters for gene
expression. This interest in the cloning and sequencing of a 
number of genes of the B .subtilis chromosome and those of 
its phage being greatly stimulated not by potential 
industrial applications but by the regulatory comparisons so 
far drawn with E .coli which have highlighted intriguing 
differences in the methods by which the organisms regulate 
gene expression.
1.6.2 Shuttle vectors
Many of the plasmids which have been constructed for
the purpose of expressing cloned genes in B.subtilis,
including those used in this work, have proven to be useful 
in demonstrating these regulatory differences and in 
providing ease of technical manipulation. This has been 
achieved by constructing these plasmids as hybrids 
containing two replicons, one capable of replication in 
E.coli and the other in B .subtilis, each carrying selectable 
antibiotic resistance markers (50,55,56). Such shuttle 
vectors are subsequently capable of propagation in either 
host, enabling studies on the expression of genes cloned 
into the plasmid in either organism. The principal advantage 
of these plasmids is that in addition to providing 
controlled comparisons of gene expression they permit much 
of the difficult manipulation often involved in plasmid 
construction to be carried out in the more easily handled 
E .coli host. Subsequent transformation of competent 
B .subtilis can then be carried out using high concentrations 
of purified and characterised plasmid.
-28-
These vectors however are not entirely free of 
problems. Often they have displayed structural instability 
in B .subtilis (57,58) and sometimes in E .coli (59). As yet 
none have been engineered extensively enough to be suitable 
for widespread application. There are indications 
nevertheless that the use of site-directed mutagenesis and 
rapid oligonucleotide synthesis may in future yield more 
versatile vectors, perhaps possessing multiple unique 
cloning sites, in the manner of the pUC (46,60) vectors of 
E .coli. The problem of plasmid structural instability in 
B .subtilis however, remains relatively unresolved. Although 
recombinational deficient (recE) hosts can be used to reduce 
these occurences (61), some recE independent rearrangements 
still occur (58). The mechanism of this event is still 
unclear.
In this work, careful consideration has been given to 
these aspects of the use of shuttle vectors and a shuttle 
system has been designed primarily to study the expression 
of 3-urogastrone in both hosts, but which should prove 
versatile for more widespread application and which 
minimises the problems of vector instability. The regulatory 
elements of gene expression have been incorporated as easily 
replacable units and unlike any other reported shuttle 
vectors, the entire E .coli replicon, in this case pATl53 is 
removed prior to transformation of B .subtilis. This reduces 
the likelyhood of plasmid rearrangement and facilitates 
oligomerisation of the plasmid, necessary for uptake by 
competent B .subtilis cells (62). The series of plasmids 
derived from the parent vector has been used to examine the 
expression of the synthetic gene in B .subtilis and in 
E.coli.
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The recent nucleotide sequencing of a number of 
cloned genes of the B.subtilis chromosome has begun to 
explain a perplexing contrast in the expression of genes in 
B .subtilis and in E .coli. That is: the observation that 
although B .subtilis genes are often expressed with 
reasonable efficiency in E .coli, normally E .coli genes are 
not expressed in B .subtilis. This has been shown to be due 
to regulatory differences between the two organisms occuring 
both at the level of transcription and translation. Although 
the most directly significant block to the expression of 
E .coli genes occurs at the level of translation in 
B .subtilis, it is the differences in transcriptional 
regulation which have been most intensely investigated for 
their role in the development of the process of sporulation. 
There are some indications from these studies why many 
E .coli genes are poorly or not at all transcribed in 
B .subtilis.
1.6.3 Contrasts of transcriptional regulation in E .coli and
B .subtilis
As in E .coli, the RNA polymerase of B .subtilis
consists of a "core" molecule comprising three proteins, a, |3
and 0', in the ratio 2:1:1. Associated with this core
molecule is another peptide known as sigma (a) which is
responsible for conferring specificity upon the polymerase
to recognise and to initiate transcription at particular
promoter sequences in the genome. In E .coli only one form of
the a peptide has been detected, a 70 kDal m.wt. peptide 
70(a ) (63), although very recently there have been reports 
of a sigma like protein being induced during the heat shock 
response (64). However in B .subtilis the core polymerase can 
interact with a number of sigma-like proteins. The principal 
form of a factor detected in vegetatively growing B .subtilis 
cells is a 43 kDal m.wt. peptide designated (65). This
is very homologous to the sigma factor of E .coli. However in
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the response of B .subtilis to nutrient depletion in which
the bacterium enters a developmental pathway culminating in
the development of the endospore at least five temporally
defined classes of genes are expressed. The expression of
these genes can be correlated with the appearance of
sigma-like proteins which bind to and modify the promoter
specificity of core RNA polymerase (66). RNA polymerase
43modified by the presence of a a factor other than a 
recognises and selectively transcribes different classes of 
promoter sequences (67). A similar form of transcriptional 
regulation occurs during the development of certain phage 
infections of B .subtilis in which the phage genome encodes 
novel <t factors (6 8 ) which temporally regulate its 
expression. The core polymerase of B .subtilis, differs 
however in a further respect from that of E .coli, in that it 
associates with an additional peptide known as the delta 
(69) factor. This 21 kDal m.wt. peptide appears to enhance 
the interaction of polymerase with promoter regions without 
affecting the specificity of promoter sub-class recognition.
As yet insufficient genes of the B .subtilis
chromosome have been sequenced to allow extensive
comparisons of the primary sequence homologies within and
between these promoter sub-classes. Nevertheless some
homologies have been detected and consensus sequences
assigned, particularly for promoters recognised by the major
43form of the RNA polymerase, that containing a . Comparisons
between these and E .coli promoter sequences show that both
display the same consensus hexamers of DNA sequence located
at -10 bases and -35 bases from the transcription initiation
point (70). However, the individual sequences of B.subtilis 
43a promoters display far less variation from these 
conserved hexamers than do their E .coli counterparts (70). 
This apparent difference in stringency may simply reflect 
the far fewer numbers of B .subtilis promoter sequences yet 
determined but seems to indicate a greater conservation of
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DNA structure which may be required for recognition and
initiation of transcription by the RNA polymerase. Certainly
43it is consistent with the observation that a promoter 
sequences from B .subtilis are more frequently transcribed 
efficiently in E .coli than are E .coli promoters in 
B .subtilis. The use of random and site-directed mutagenesis 
has already clearly demonstrated that in E .coli certain 
nucleotides within these conserved regions are essential for 
efficient transcription from particular promoters (30). 
Similar studies in B .subtilis are likely to show whether or 
not B .subtilis is more sensitive to particular changes in 
promoter DNA sequence and may demonstrate mutations which 
can be made to promoter regions of E .coli in order to 
increase the efficiency by which they are transcribed in 
B.subtilis.
1.6.4 Choice of promoter
This work describes the cloning, sequence analysis 
and characterisation of a promoter region derived from the 
B .subtilis bacteriophage SPPl. Although a virulent phage, 
SPPl infection does permit host DNA, RNA and protein 
synthesis for some time after infection, a feature more 
characteristic of infection by temperate phage. The linear 
phage genome is approximately 43 kb in length with many 
phage genes and proteins identified (71,72). The promoter 
isolated in this work has previously been shown to be one of 
five major early promoters on the SPPl genome (73). It is 
transcribed immediately after infection and continues to be 
active throughout infection, either in the presence or 
absence of chloramphenicol (74). This is indicative of 
transcription by unmodified host polymerase but does not 
rule out, the possibility of any additional transcription by 
modified forms of polymerase, as has been shown to be the 
case for phage SPOl (75). The existence of SPPl specified 
RNA polymerase modifying factors has not been demonstrated
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although late phage genes do require de novo protein 
synthesis for transcription (74). This promoter has also 
been shown to initiate transcription in vitro more strongly 
than any of the other early SPPl phage promoters, using RNA 
polymerase from both B .subtilis and E .coli (73). The genome 
of phage SPPl has been restriction mapped in detail and the 
promoter shown to reside on a 1.4 kB EcoRI restriction 
endonuclease fragment. In addition the approximate position 
of transcription initiation within this fragment and the 
direction of transcription have previously been shown (73) 
and are verified in this work. Recent publication (76) of 
nucleotide sequence from this fragment differs substantially 
from that determined in this work as discussed in Chapter 5.
This promoter region therefore seemed appropriate for 
DNA sequence analysis and determination of the RNA 
polymerase binding sites and transcription start point in 
both B .subtilis and E .coli. It also provided an efficient 
transcription regulatory region to combine with specific 
regions of translational regulation for the study and 
comparison of heterologous gene expression in both hosts.
1.6.5 Contrasts of translational regulation in E.coli and
B .subtilis
The role of specific nucleic acid sequences in the 
regulation of translation has similarly been examined and 
compared in E.coli and B .subtilis. As before, the vast 
majority of sequence data which has been determined to date 
is of the E .coli chromosome or of coliphage. Nevertheless, 
the DNA sequences encoding ribosome binding regions of 
B .subtilis mRNA species have indicated possible explanations 
for the non-translation of E .coli derived messenger RNA's in 
B .subtilis. This is based on the nature of the various 
components of the classically defined ribosome binding site. 
In both E .coli and B .subtilis, ribosome binding sites are
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regions of an mRNA sequence at which ribosomes will 
specifically bind and initiate protein synthesis. They 
comprise a region of base complementarity to the 16S 
subunit of ribosomal RNA, the Shine-Dalgarno (S.D.) box 
(77), followed at an appropriate distance by a methionine 
initiator codon, usually ATG where protein synthesis 
initiates. The degree of complementarity to the ribosomal 
RNA and the number and content of the intervening bases 
between this region and the initiation codon are crucial for 
efficient initiation of translation in either organism (32). 
However, these paramaters appear to be more influential on 
efficient translation initiation in B .subtilis than they are 
in E .coli since the ribosome binding sites of B .subtilis and 
other gram-positive derived mRNA's display consistently 
higher complementarity to the 16S rRNA subunit than do 
mRNA's derived from E .coli (70). The calculated free 
energies of base-pairing interacton of these regions give an 
average value of -17 kcal for B .subtilis and -11 kcal for 
E .coli. This has led to the hypothesis that B .subtilis 
requires a stronger interaction of these regions to form an 
efficient translation initiation complex (78). This is not 
generally reflected in the other components of the 
translational machinery since most of these can be 
successfully interchanged between these organisms and also 
between E .coli and other gram-positive organisms such as 
Bacillus stearothermophilus. E .coli elongation factors EF-G 
and EF-Tu can complement temperature sensitive lesions in 
B .subtilis protein synthesis systems and vice versa (79).
B .stearothermophilus 16S rRNA can be used to reconstitute 
30S ribosomes with E .coli 30S ribosomal proteins and vice 
versa and E .coli 5S and 23S rRNA can likewise be used to 
reconstitute 50S ribosomes in the presence of 
B.stearothermophilus 50S ribosomal proteins (80). A good 
illustration of the molecular basis of interchangeability of 
some components is observed when the N-terminal amino-acid 
sequences of all the 30S ribosomal proteins and several of
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the 50S proteins from the three organisms are compared (81). 
In these there is 84% correlation between the two bacilli 
and 50% between B .stearothermophilus and E .coli .
Nevertheless, certain ribosomal proteins have been 
implicated in the translational differences observed between 
E .coli and B .subtilis in ways consistent with the 
differences now apparent in their mRNA ribosome binding. The 
E .coli ribosomal protein SI has been shown to confer upon 
B .stearothermophilus the ability to translate the coliphage 
R17 hitherto untranslated replicase and coat proteins (82). 
Protein Si is involved in the binding of mRNA to the 
ribosome possibly by stabilising the interaction of the S.D. 
region and the 16S rRNA. The implication is that this or 
other salt dissociable factors are required for translation 
of mRNA's from gram negative but not gram positive 
organisms. This is consistent with the stronger 
complementarity observed between the B .subtilis mRNA's and 
the 3' end of the ribosomal 16S RNA suggesting that this 
stronger interaction precludes the need for such factors 
required by E .coli. If as hypothesised, B .subtilis does 
require a more stringent base pairing for efficient 
translation then most E .coli mRNA's would not base-pair 
sufficiently to be translated in B .subtilis and this could 
explain the translational discrimination seen against most 
E .coli genes.
»
Considering this fact it is possible to design 
putative DNA sequences which when transcribed could act as 
ribosome binding sites both in E .coli and in B .subtilis. It 
should also be possible to evaluate in both hosts the effect 
of variations in the complementarity of synthetic ribosome 
binding sites to the 3' end of the 16S RNA subunit. The 
secondary structure of messenger RNA has also been shown 
both in E .coli (33) and in B .subtilis (60) to be crucially 
involved in translational efficiency. This must also be 
considered in conjunction with RNA primary strucure. However
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using sophisticated computer assistance to predict the 
effects on secondary strucure of changes in primary 
structure of RNA as with DNA in gene design, it is possible 
to avoid the introduction of stable duplex structures which 
have been shown to exert an effect on the regulation of 
translation.
Taking this into account, expression systems were 
designed, based on the shuttle plasmid system derived from 
vectors pATl53 and pUBllO. These incorporated the promoter 
from phage SPPl with synthetic ribosome binding sites 
designed to effect efficient translation of 0-urogastrone in 
both B .subtilis and E .coli. The vectors were intended to 
facilitate technical manipulation, to enable the expression 
of different genes and to allow the simple replacement of 
the synthetic ribosome binding region. Subsequent 
oligonucleotide directed mutagenesis was used to examine the 
effect of translation initiation from the ribosome binding 
region immediately downstream of the SPPl promoter.
This then provided a versatile system to study the 
expression of |3-urogastrone and subsequently other peptides 
in Bacillus subtilis. It also provided a means to examine in 
E .coli the initiation and efficiency of transcription from a 
promoter derived from a B .subtilis phage and to evaluate in 
both hosts the use of synthetic ribosome binding sites in 
gene expression.
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CHAPTER 2 
MATERIALS AND METHODS
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2.1 Chemicals
General reagents used in this work were supplied by 
BDH chemicals. Amino acids, carbon sources and specialist 
reagents were from Sigma Biochemicals. Ultra pure acrylamide 
and phenol were supplied by Bethesda Research Laboratories. 
Sephacryl S300 was supplied by Sigma.
2.2 Radiochemicals
All radiochemicals were supplied by Amersham 
International.
2.3 Enzymes
All restriction endonucleases were supplied by New 
England Biolabs or Bethesda Research Laboratories (B.R.L.).
E .coli DNA Polymerase (holoenzyme) used in blunt end 
generation, was from Biolabs. E .coli DNA Polymerase (Klenow 
fragment) used in DNA sequencing and site directed 
mutagenesis, was obtained from Boehringer Mannheim. 
Polynucleotide kinase was obtained from P.L. Laboratories 
and T4 DNA ligase, AMV reverse transcriptase and Si nuclease 
from Biolabs. Ribonucleases A and Tl were obtained from 
Sigma.
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2.4 Bacterial Strains
The following bacterial strains were used in this work.
E .coli K-12
HB101 - leu, ££0 , thi, lacY, recA, rk“mk“ , rpsL, endA
(83).
HW87 - araDl39(ara-leu)del7697, (lacIPOZY)de!74, galU, 
galK, rpsL, rk“ rocA56, TnlO::Tcr (84).
HW27 - thrl, leuB6 , thil, argE3, his4, proA2, lonl,
lacYl, galK2, mtll, xy!5, ara!4, rpsL, tsx33, supE44
(84).
JM101 - (lac-pro)del, supE, thil; F' proA+B+ , laclq ,
lacZdelMl5, tra de!36 (85).
B .subtilis
3G18 - ade, met, trpC2 (86).
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2.5 Plasmids and Phages
All plasmids used in this work are listed below
pATl53
pUBllO
pFF2
pFF4
pFF401
pFF501
pLFl
pURl
pUR2
pUR3
pWT221
221-URO
PWT571
571-URO
pMCl403
pFF710
pFF730
pFF700
pFF740
pFF710R
pFF710L
dual-replicon pATl53+pUBllO. 
pFF2 + SPPl fragment 10. 
pFF4 deleted in one Eco RI site. 
pATl53 + p-urogastrone and R.B.S. I. 
pATl53 + Eco RI to Bam HI 
fragment of pUBllO.
C-terminal fragment of p-urogastrone
cloned into pLFl.
pURl + Hind III site.
pUR2 + N-terminus of 0-urogastrone.
pATl53 based version of pWTl21
0-urogastrone gene cloned into pWT221
p-urogastrone gene cloned into pWT571
shuttle plasmid + SPPl promoter 
R.B.S. I and @-urogastrone. 
as pFF710 with R.B.S. II replacing 
R.B.S. I.
as pFF710 with R.B.S. I deleted, 
as pFF700 with the SPPl Pvu II to 
Eco RI fragment deleted, 
as pFF710 with pATl53 in the 
reverse orientation.
as pFF710R with the Bam HI to Aha III 
fragment of pMCl403 (containing most 
of the lacZ gene of E .coli) inserted 
between the Bgl II site of 
3-urogastrone and the Nru I site 
of pATl53.
(87). 
(52). 
(fig 2 1 ) 
(fig 2 1 ) 
(fig 2 1 ) 
(fig 2 1 )
(fig 1 1 )
(fig 1 2 ) 
(fig 14) 
(fig 15)
(38)
(Chap.4)
(39)
(Chap.4)
(88)
(fig 2 1 )
(Chap.5) 
(Chap.5)
(Chap.5)
(Chap.5)
(Chap.5)
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pFF730L as pFF710L with R.B.S. II replacing 
R.B.S. I. (Chap.5) 
(Chap.5)PFF700L as PFF710L with R.B.S. I deleted. 
pFF740L as PFF700L with the SPPl Pvu II to
Eco RI fragment deleted. (Chap.5)
Phage M13 mp8 and mp9 (45).
2.6 Media
Hallewell modified minimal media
1 x M9 salts, 2.5% glucose, 2.5% casamino-acids, 
O.lmM CaC^, lmM MgC^/ Bl O.lmg/ml.
Luria broth (per litre): Difco bacto tryptone (lOg), 
Bacto yeast extract (5g), NaCl (5g);adjusted to pH7.2.
L-Agar plates were used for growth of E .coli and 
Tryptone Blood Agar Base plates for growth of B .subtilis.
For biological assay, the growth of cells expressing 
(3-urogastrone from the trp promoter, was in Hallewell 
modified minimalmedia, supplemented where appropriate with 
tryptophan (40ug/ml).
In all other cases bacteria were grown in Luria broth 
supplemented where appropriate with antibiotics (E .coli - 
lOOug/ml ampicillin, B .subtilis - 5ug/ml kanamycin) both for 
plasmid preparation and for assay of p-urogastrone and 
0-galactosidase.
2.7 Growth of bacteria
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2.8 Synthesis of the oligonucleotides
All oligonucleotides used in this work were 
synthesised by the oligonucleotide synthesis group of the 
organic chemistry department at G.D.Searle.
Analytical grade reagents were used for the chemical 
synthesis of the oligodeoxynucleotide blocks.
4,4'-dimethoxytrityl,N-acyl protected nucleosides were 
obtained from Lancaster synthesis and further purified by 
silica gel chromatography. HPLC purification was performed 
on a Dupont 830 liquid chromatograph.
Each of the oligonucleotides of the synthetic 
p-urogastrone gene was synthesised by the solution phase 
phosphotriester procedure, coupled to rapid HPLC separation 
of final products from intermediates.
Starting materials for the syntheses were the 
5'-0-(di-p-methoxytrityi)-3'-p-chlorophenol 0-cyanoethyl
c.
phosphate derivatives of : N -benzoyladenosine,
4 2N -benzoylcytidine, N -isobutyryl guanosine and thymidine.
5'-dimethoxytrityl protecting groups were removed with 2 %
benzene sulphonic acid in chloroform/methanol (7:3 v/v) for
5 minutes at 0°C and cyanoethyl protecting groups were
removed by treatment with pyridine/triethylamine (1:1 v/v)
for 2 hours at 40°C.
Typically 80mg of the 5'-hydroxyl component was 
condensed with a 1.5 X molar excess of the 3 f-phosphodiester 
component in anhydrous pyridine in the presence of a 3 X 
molar excess of the coupling agent
2,4,6-tri-isopropylbenzene sulphonyltetrazolide. After 1 
hour or when the 5'-hydroxyl component was used up (as 
judged by silica TLC eluted with 10% methanol in chloroform) 
the reactions were quenched by the addition of 5% (w/v)
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aqueous sodium bicarbonate and extracted with chloroform.
The chloroform extracts were dried with sodium sulphate and 
chromatographed on 15-25um ODS silica using a solvent 
gradient from chloroform/methanol/water (2:6:3 v/v) to 
chloroform/methanol/water 2:6:0.5 v/v). Complete separation 
was obtained in under two hours and the fractions containing 
product extracted into chloroform, dried and evaporated 
under vacuum. Yields varied between 50-80%.
This process was repeated as necessary until at the
completion of the synthesis, all the protecting groups were
removed by sequential treatment with 0 .5M 
1 1 2  2N ,N ,N ,N ,-tetramethyl guanidinium 4-nitrobenzaldoximate 
in dioxan/water (1:1 v/v) at room temperature for 60 hours, 
concentrated ammonia at 70°C for 4 hours and 80% aqueous 
acetic acid at room temperature for 30 minutes. After 
evaporation, an aqueous solution of the oligonucleotide was 
extracted with diethyl ether and filtered. The product was 
purified by chromatography on a Partisil 10 SAX HPLC column, 
using a solvent gradient from 1M to 4M triethylammonium 
acetate pH 4.9 at 50°C. Sequence analysis was carried out 
using the mobility shift method of Wu et al (89).
Synthesis of the synthetic ribosome binding sites was 
carried out at a later date using solid phase 
phosphotriester chemistry (90). Oligonucleotides were then 
synthesised on a 2% cross-linked polystyrene support and
syntheses carried out in a continuous flow column apparatus.
32Completed oligonucleotides were 5' P phosphorylated, 
characterised and purified if necessary from 20% denaturing 
polyacrylamide gels. Primers used in the dideoxy chain 
termination sequencing of the SPPl fragment were synthesised 
using an Applied Biosystems 380B DNA synthesiser.
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2.9 Assembly of the (3-urogastrone gene
2.9.1 Phosphorylation of oligonucleotides
Molar equivalents (approximately 2ug) of each of the 
12 oligomers comprising the C-terminal half of the gene were 
phosphorylated using 4 units of T4 polynucleotide kinase in 
20ul of a solution containing 50mM Tris-HCL (pH 7.8), lOmM 
MgC^, 0.25mM ATP (including 40uCi dried down ^ P  labelled 
ATP) and lOmM BSH for 15 mins at 37°C. Due to problems of 
incorrect fragment annealing, larger quantities of some 
oligomers of the N-terminal half of the gene (up to 7ug) 
were phosphorylated and combined in molar ratios of 0.5:1. 
Following reaction the enzyme was inactivated by incubation 
at 90°C for 5 mins. Each oligonucleotide was then visualised 
by autoradiography following electrophoresis of lul of 
reaction mix in a total volume of 12ul, including 6% ficoll 
loading buffer, on a 20% polyacrylamide/7M urea gel.
2.9.2 Ligation of oligonucleotides
The remaining volumes of each phosphorylated oligomer 
were then combined as described in the results section and 
conditions adjusted for ligation. Ligation of oligomers was 
carried out using 6 units of T4 DNA ligase in a solution 
containing 50mM Tris pH 7.8, lOmM MgC^/ lmM ATP, 20mM DTT 
for 8 hours at 25°C. Ligation products were characterised by 
electrophoresis of 3ul aliquots on 20% native and denaturing 
TBE poly-acrylamide gels. Fragment sizes were accurately 
sized using a ladder of ligated lObp long Hind III linkers 
run in parallel.
2.9.3 Gel Electrophoresis
All poly-acrylamide gels used other than in DNA 
sequencing were 30cm x 12cm x 1.5mm. They were prepared from 
30% stock (29%-Acrylamide, 1% Bis-acrylamide) and run in 
buffer TBE (90mM Tris HCL pH 8.3, 90mM boric acid, 2.5mM
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EDTA ). Gels were polymerised by addition of 400ul of 10% 
Ammonium Persulphate and 30ul TMED to lOOmls of 
acrylamide/TBE solution. Electrophoresis was typically 
carried out for 16 hours at 300V. Denaturing gels were as 
native gels but included 7M urea. Gels used in DNA 
sequencing were 30cm x 20cm x 0.8mm. They were prepared as 
6% (5.8% acrylamide - 0.2%-Bis-acrylamide) stock solutions 
containing 1 x TBE and 7M urea. Gels were polymerised by 
addition of 300ul of 10% ammonium persulphate and 40ul TMED 
to 50mls of acrylamide/TBE/urea. Electrophoresis was carried 
out for 2-6 hours at a constant power of 40W, depending on 
the extent of sequencing required.
Agarose gels were run on flatbed systems of 20cm x 
15cm or 10cm x 8cm submerged in buffer TBE. For 
visualisation or extraction of specific fragments less than 
200 bp in length, 2% gels were used. All other gels were of 
1% agarose. For extraction of fragments, low gelling 
temperature agarose was used. Marker fragments of phage X 
DNA digested with Hind III and phage <f>Xl74 digested with Hae 
III were used on all gels. For fragment sizes see Appendix 
2.
2.9.4 Extraction of assembly intermediates
Gel slices containing correctly ligated assembly 
intermediates were excised following superimposition of 
exposed autoradiographs onto native polyacrylamide gels. 
Extraction of DNA from gel slices was carried out by 
electroelution onto a 5mm column of DE52 DEAE cellulose 
placed between two GFC discs within a 2ml syringe. The gel 
slice was contained within a 1ml Gilson micropipette tip 
placed within the syringe and the syringe fixed within a 
tube gel electrophoresis apparatus. Maximum transfer of DNA 
to the DEAE cellulose (>90%) occurred after 1 hr of 
electrophoresis at 200V. The DE52 was then washed in buffer 
containing 2mM magnesium acetate, 0.02% w/v SDS and 20mM
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EDTA and the DNA eluted in 2ml of the same buffer containing 
1.1M NaCl. The solution was diluted three-fold and the DNA 
recovered by ethanol precipitation. Recovery from the DEAE 
cellulose varied between 75-90%.
2.10 Cloning
2.10.1 Restriction fragment isolation
All restriction endonucleases were used according to 
manufacturers’ recommendations. Analytical agarose gels were 
0.8%, 1%, or 1.5% and were run in 1 x TBE buffer. All 
restriction fragments used in the cloning of the urogastrone 
gene were isolated by electroelution from 1% TBE agarose 
gels using the same apparatus and procedure as for 
polyacrylamide gel elution. Restriction fragment recovery 
from polyacrylamide gels was by electro-elution.
Restriction fragment isolation in subsequent cloning 
procedures was carried out by extraction from low gelling 
temperature agarose. Fragments were visualised by long wave 
UV irradiation following staining by ethidium bromide 
(lOOng/ml) and excised in as small a volume as possible 
(typically lOOul). The fragment was then melted at 65°C in a 
total volume of 500ul in 300mM NaAc, lOmM Tris pH 8 , ImM 
EDTA. In all cases except isolation of the fragment for in 
vitro transcription, 5ug/ml carrier tRNA was also added. 
Agarose was then removed by three extractions with phenol 
(v/v 1 :1 ), and traces of phenol removed by 2 extractions 
with ether (v/v 1:1). Fragments were then precipitated by 
addition of 2.5 volumes of ethanol and storage for lhr at 
-20°C and recovered by centrifugation for 10 minutes in an 
Eppendorf microfuge. Fragments were washed once in 70% 
ethanol and taken up in a volume of 20ul of water.
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2.10.2 Fragment ligations
Ligation of fragments was carried out typically in a 
volume of 20ul containing lOOmM Tris pH7.5, lOmM MgC ^ /  10mM 
{3-mercaptoethanol, 2mM ATP. Ligations of fragments 
possessing complementary ends were carried out for 4 hrs at 
25°C. Blunt end ligations were carried out overnight at 
15°C.
2.10.2 Preparation of plasmid DNA
Plasmid DNA was initially prepared from E .coli by the 
cleared lysate method (39). This was later replaced by the 
alkali denaturation method of Birnbaum and Doly (91). For 
large scale preparations, (50 mis of cells ), the use of 
ultracentrifugation was replaced by gel filtration. Final 
precipitates of DNA prepared by the alkali denaturation 
method were taken up in a total volume of 200ul containing 
lOmM Tris pH8 , ImM EDTA, lOOug/ml RNase A, 20ug/ml Rnase T l , 
and incubated for 30 mins at 37UC. To this was then added 
20ul of 100% glycerol and the total volume loaded onto a 
30cm x 15mm column of Sephacryl S300. Column buffer of lOmM 
Tris pH8 , ImM EDTA, 150mM NaCl was pumped at a flow rate of 
2mls/min. Detection of nucleic acid was by an in-line LKB 
Uvicord detector linked to a Kipp and Zonen BD40 chart 
recorder. PLasmid DNA yields of 50-200 ug could typically be 
collected over a period of 30 mins in a volume of 5-7mls, 
entirely free of contaminating cellular RNA, and 
precipitated in 2.5 volumes Of ethanol at -20°C.
Plasmid DNA from B .subtilis was also isolated by the 
cleared lysate method but no clearing spin was done. DNA was 
instead purified by two consecutive ultracentrifugations for 
16 hours at 36K rpm in a Beckman Ti60 vertical rotor.
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Small scale preparations of DNA (1ml), were carried 
out in E .coli by the alkali denaturation method employing 
only one phenol extraction step (v/v 1 :1 ) and two ether 
extraction steps (v/v 2:1) prior to precipitation. Small 
scale preparations of B .subtilis DNA was done by the alkali 
denaturation method with the solution 1 incubation step 
carried out for 30 mins at 37°C.
2.10.4 Transformation
Transformation of all strains of E.coli was carried 
out according to the Ca^+ treatment method (92) and 
transformation of B .subtilis was by the method of Arwert and 
Venema (8 6 ). Preparation of all shuttle plasmids excepting 
those incorporating the lacZ fragment, for transformation of 
B .subtilis involved cleavage with Bam HI followed by 90°C 
incubaton for 10 minutes to destroy the enzyme, addition of 
l/10th volume of lOx ligation buffer, lul ligase and 
ligation for 4 hours at 25°C. The entire mix was then used 
in the transformation. Shuttle plasmids incorporating the 
fragment of lacZ were linearised by cleavage with Bgl II and 
religated as before.
2.10.5 Si nuclease and DNA polymerase
Treatment of DNA fragments with Si nuclease and DNA 
polymerase was carried out using standard methodology.
2.11 DNA Sequencing
All DNA sequencing was carried out by the dideoxy 
chain termination method (93). Sequencing reactions were 
carried out in micro-titre wells. All primers were annealed 
to template DNA for 30mins at 55°C.
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2.12 Site Directed Mutagenesis
Site directed mutagenesis of the SPPl promoter region 
was carried out using the method of Zoller and Smith (94).
2.13 Oligonucleotide primed reverse transcription
2.13.1 RNA preparation
Total cell RNA was prepared from E .coli and 
B .subtilis as follows. A fresh colony was used to inoculate 
an overnight culture of cells, grown in L-broth under 
antibiotic selection. The following morning 50mls of cells 
in a 1 litre baffled shake flask were inoculated at O*d *6Q0 
of 0.01. Cells were grown to an 0.D .^qq of 0.5 wherupon 10 
mis of cells were spun at 10,000 rpm for 1 minute. Cells 
were washed in 10 mis buffer A (lOmM Tris pH 7.5, 5mM M g C ^ /  
lOmM KCl,), and re-pelleted for 1 minute. The supernatant 
fluid was removed and cells taken up in 2mls of buffer A 
plus 300ug/ml T4 lysozyme. Cells were immediately frozen in 
liquid nitrogen and then placed in a 65°C bath for 3 
minutes. A volume of 220ul of 10% SDS was then added at 
which point the solution became totally clear. To this 
solution was added 80ul of 3M NaAc pH 5.2 and an equal 
volume of phenol pre-heated to 65°C. The mix was then 
vortexed for 20 seconds and spun for 5 minutes at 10,000 
rpm. The aqueous layer was removed along with any interface 
and the process repeated until little or no interface was 
evident (typically 4 or 5 times). The aqueous layer was then 
extracted twice with an equal volume of ether. NaCl was then 
added to 2M and the nucleic acid precipitated by addition of
1.5 volumes of EtOH and storage at -20°C for 30 minutes. The 
nucleic acid was then spun at 10,000 rpm for 10 minutes, 
dried and resuspended in 1ml H2O. When dissolved NaCl was 
added to 3M and the solution incubated overnight at 4°C to 
selectively precipitate the RNA. This was then spun as
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before, washed in 70% EtOH 3x, dried and taken up in 200ul 
H2O. This was then stored at -70°C. Yields were between 
100-400ug from lOmls of cells.
2.13.2 Reverse transcription to identify transcription
initiation point
Reverse transcription of messenger RNA prepared as 
above was carried out in a micro-titre well. Approximately 
2ug OF RNA was annealed to approximately 2.5ng of 
oligonucleotide primer in a lOul solution containing lOmM 
Tris pH7, 5mM MgC^/ and allowed to anneal at 55°C for 30 
minutes. To this was then added lul of dNTP mix (1mm each of 
GTP, CTP and TTP), lul of 35S ATP, and lul of reverse 
transcriptase, and the mixture incubated for 30 minutes at 
37°C. To this was then added 5ul of formamide dye mix (100% 
deionised formamide, 20mM EDTA, 0.03% XCFF and BPB) and the 
mixture heated to 80°C for 15 minutes. This was then 
electrophoresed on a normal sequencing gel along with 
appropriate sequence reactions as indicators.
2.14 Transcription and translation in vitro
In vitro transcription and translation of plasmids 
and purified fragment was carried out using a prokaryotic 
DNA directed translation kit (Amersham).
2.15 Plasmid copy number determination
Plasmid DNA was isolated from a cell pellet 
equivalent to 1ml of cells of O.D.^qq 2.0, by extraction 
with unequilibrated phenol/chloroform. Plasmid DNA was then 
electrophoresed on a 1% TBE agarose gel, along with standard 
amounts of pATl53 DNA. Following ethidium bromide staining, 
a photograph of the gel was scanned using a Chromoscan 3 and
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copy number determined from peak integral values.
2.16 Preparation of cells for biological assay
2.16.1 Cells containing trp promoter regulated 
p-urogastrone gene
Cultures of lOmls of Hallewell minimal media 
supplemented with L-tryptophan (40ug/ml) and ampicillin 
lOOug/ml, were inoculated from a glycerol stock of cells and 
grown overnight at 37°C. These were then used to inoculate 
300ml cultures of Hallewell minimal media supplemented with 
ampicillin (lOOug/ml) at an initial O*D *gQ0 anc* 9rown
at 37°C in 11 shake flasks. Growth was monitored by 
absorbance at O.D.^qq until at approximately O.D.gQQ-0.4 a 
pre-induction 1ml sample was taken for assay. Expression 
from the trp promoter was then induced by addition of p-IAA 
(final concentration 20ug/ml). Further 1ml samples for 
biological assay were removed at time intervals of 15, 60, 
90, 120, 150, 180 and 240 minutes following induction. Cell 
samples were then prepared as folows.
lml cell sample + 60ul (25% sucrose/50mM Tris pH7.4)
Kept on ice 5 minutes.
Addition of 20ul of lOmg/ml lysozyme in PBS.
Kept on ice 5 minutes.
Addition of lul PMSF (35mg/ml in EtOH) and 20ul 500mM EDTA 
pH 8.0.
Kept on ice 5 minutes.
Addition of lOOul of 0.6% Triton TX-100
Cells were then shaken vigorously at room temperature for 5 
minutes and spun in an Eppendorf microfuge for 10 minutes. 
The supernatant volume of 200ul was removed and added to 
1400ul of PBS. This was then dialysed over 24hrs at 4°C 
against PBS and then stored at -20°C prior to receptor 
binding or radio-immuno assay.
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2.16.2 Cells containing SPPl promoter regulated
p-urogastrone gene
Cultures of lOmls of L.broth supplemented with 
appropriate antibiotics were inoculated from a fresh streak 
of E .coli or B .subtilis and grown overnight at 37°C. These 
were then used to inoculate 100 ml cultures of L.broth 
supplemented with antibiotics and grown at 37°C in 11 shake 
flasks. Growth was monitored at O.D.^qq until at O.D.^qq 0.3 
the first 5ml sample was taken for assay. Further samples 
were taken at intervals of 15, 60, 90, 120, and 150 minutes. 
Samples were concentrated 10 fold in buffer containing 50mM 
Tris pH7.5, ImM PMSF, and 5M urea and sonicated for 2 x 30 
seconds on ice in a sonicator. Extracts were spun for
10 mins in a microfuge and the supernatant volumes of 500ul 
removed and dialysed overnight. Samples were then assayed by 
radio-immuno assay.
2.16.3 Cells containing urogastrone/g-galactosidase
peptide fusions
Cultures of lOmls of L.broth supplemented with 
appropriate antibiotics were inoculated from a single colony 
from a fresh streak of cells and grown overnight at 37°C. 
These were then used to inoculate 50mls of antibiotic 
supplemented L.broth culture grown in 11 shake flasks. At 
O.D.goo ^he first 1ml sample was taken. Further samples were 
taken at intervals of 15, 45, 75, 135 and 195 minutes. All 
samples were concentrated twofold in buffer BB (42) and 
lysed by sonication for 2 x 30 seconds on ice. Samples were 
spun 10 mins in a microfuge and supernatant fractions 
removed for assay.
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2.17 Assays
2.17.1 g-urogastrone receptor binding assay 
Reagents
Cell Growth Medium:
RPMI 1640 (Bicarbonate buffered) + 10% foetal calf 
serum.
Diluent for Standards and Samples:
RPMI 1640 (Hepes buffered) + 0.1% Human serum albumin.
Cells:
Vero (African green monkey kidney)
Standards: 200, 100, 50 and 25 ng/ml.
125 I g-urogastrone:
After iodination and chromatography, aliquots of the 
peak fractions are diluted for testing in order to give 
about 5000cpm/10ul. At these dilutions the individual 
fractions are tested under assay conditons for specific and 
non-specific binding. Those giving maximum specific with 
minimum non-specific binding are pooled, re-checked in assay 
and stored at -30°C.
\
Dilution of test samples
An estimate of the g-urogastrone concentration 
provides the dilution factor required to ensure that the 
result will fall within the limits of the standard curve. At 
least three replicates of each dilution are assayed.
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Growth of: monolayers
Vero cells are seeded into 24 well plates, l.Oml/well 
at 400,000 cells/ml in RPMI 1640 + 10% feotal calf serum. 
Cells are incubated at 37°C in 5% CO2 overnight.
Assay
Growth medium is removed and cells washed x3 with
PBS. To each well is added 150ul diluent, 40ul of sample and 
125lOul of I 3-urogastrone. A complete set of standards is 
included in each plate. After 1 hr at room temperature the 
well contents are aspirated and washed x4 with PBS. 500ul of 
0.1N NaOH is added to each well to lyse the cells and 
incubated at 37°C for at least 15 minutes. After mixing, 
450ul of well contents are removed for counting. 
Concentrations of @-Urogastrone in the samples are 
determined using a standard curve prepared from the set of 
standards.
2.17.2 Radio-Immuno Assay 
Reagents
Phophate Buffered Albumin (PBA) 0.05M:
40mM Na2HP04, llmM NaH2PC>4, 0.1% NaN3, 0.5% BSA. 
Stored at 4°C.
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Immunoprecipitin (Fixed Staphylococcus aureus cells)
Staphylococcus aureus (BRL) cells are spun at 3000 G 
for 10 mins and supernatant decanted. Cells are resuspended 
in an equal volume of PBA containing 10% w/v BSH and 3% w/v 
SDS and are mixed well. Cells are then heated to 95°C for 30 
minutes and spun at 3000 G for 30 minutes. The supernatant 
is decanted and cells resuspended to 0.75 original volume in 
PBA and stored at 4°C. Cells are used at one hundredth 
dilution in the assay.
Antibody (Rabbit anti-(3-urogastrone)
The dilution of antibody to be used in the assay is 
determined for each new batch using a series of antibody 
dilutions set up for assay against PBA to establish a value 
for non-specific antibody binding. The resulting percentage 
bindings are plotted against the dilutions and an 
appropriate antibody dilution selected.
125 I g-urogastrone
This is prepared as in the receptor binding assay. 
Standards
Standards are prepared as batches from aliquots of a 
stock solution of purified p-urogastrone stored at -70°C. 
Serial dilutions are prepared to give a range of standard 
concentrations from 4ng/ml to 128 ng/ml. Each fresh batch of 
standards is checked by assay against current standards. 
Standards are stored in aliquots of 250ul at -30°C.
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Assay
Samples are diluted in PBA, to ensure reults falling
on the standard curve. lOOul of each sample is mixed with
125
lOOul of antibody and lOOul of I 3-urogastrone. All 
samples are duplicated and a range of standards including a 
non-specific binding standard (PBA only) are included. Tubes 
are mixed thoroughly and incubated at room temperature for 
18 hours. To this is then added 1.0ml of Staphylococcus 
aureus. Samples are then allowed to stand for at least 15 
minutes and then spun at 2000 G for 20 minutes. The 
supernatant is then decanted and the cells drained 
thoroughly. Tubes are then counted. Averages are determined 
for duplicate samples and the value of the non-specific 
binding subtracted. Concentrations of |3-Urogastrone in 
samples are then determined using the standard curve derived 
from the standard values.
2.17.3 p-galactosidase assay
£-galactosidase activity was measured as described by 
Miller (42). Plates for screening of 0-galactosidase 
producing E .coli or B .subtilis colonies contained X-gal 
(40ug/ml) in L-broth or minimal media.
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CHAPTER 3
ASSEMBLY AND CLONING OF THE GENE FOR
HUMAN (3-UROGASTRONE
UROGASTRONE OLIGOMERS 
( C- terminus.) 
(No.)
20 -
23 20
22
19
size.
14
21
14
18 15 13
12
15
16 17
14
20
18
16 16
10
1
: 12 ! 1? i 14 '
: ; 12V.*.13
20X Acrylamide 
7M UREA
Figure 3. Oligomer identification.
The 12 oligomers of the C-terminal half of the synthetic
|3-urogastrone gene, visualised by auto-radiography
32following labelling with P and electrophoresis on a 20% 
denaturing poly-acrylamide gel.
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3.1 Assembly of the gene
3.1.1 Identification of the oligomers
Following deblocking, each of the oligomers to be
used in the assembly of the 0-Urogastrone gene possessed an
hydroxyl group at both the 5' and 3' termini. This
32facilitated labelling of each fragment with P ATP using T4 
polynucleotide kinase and subsequent visualisation by 
autoradiography on a denaturing poly-acrylamide/7Murea gel.
Each oligomer could thus be identified as well as 
checked for integrity, purity and correct postitioning at 
each stage in the assembly of the gene.
For simplicity the gene was assembled and cloned in 
two almost equal parts encoding the N and C termini , the 
latter being carried out first and establishing a strategy 
for the former.
Figure 3 illustrates each of the oligomers of the 
C-terminal half, with for reference markers a ladder of 
ligated Hind III linkers of 10 bp in length, giving useful 
increments up to approximately 100 base pairs. Oligomers are 
referred to by their identification number in Figure 1.
Oligomers can be seen to electrophorese as would be 
expected from their relative lengths, but obviously with 
such small fragments the purine/pyrimidine ratio has a 
relevant influence on the mobility of individual oligomers. 
There is little evidence of contaminating fragments.
3.1.2 Pre-assembly
Prior to the full-scale assembly of the gene, two of 
the oligomers were tested to determine both their ability to 
correctly hybridise and ligate and under what conditions 
this was most favoured. These oligomers, numbers 12 and 13
Lanes. 1 2 3 4 5 6 7 8 9  10 11
hours
incubation — 2 4 8 2 4 8
—30bp2x(12+13)
(12+13) — 20bp
12
13
— 10 bp
20X Acrylamide. 
Native
*
Figure 4. Dimerisation about the Xba I site.
Poly-acrylamide gel showing dimerisation occuring about
the palindromic Xba I restriction site, following
annealing and ligation of oligomers 12 and 13. Lanes 1 and
3 show oligomer 12 alone and Lanes 2 and 4 show oligomer
13 alone. The effect of duration and temperature of
ligation are shown in lanes 5 to 10. Lane 11 shows 
3 2ligated, P labelled 10 bp Hind III linkers as markers.
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form the Xbal site in the centre of the gene and upon 
hybridisation to one another would normally be expected to 
dimerise about the palindromic restriction site.
Figure 4 depicts this event, clearly illustrating the 
formation of the double-stranded DNA fragment 12+13 and the 
dimeric form 2x(12+13) whilst there is no evidence of 
incorrectly ligated material.
Variations in either, duration or temperature of 
ligation showed little effect on the products of assembly 
and it was decided that future ligations would be undertaken 
at 15° C for 4 hours.
In order to demonstrate that the large band in Figure 
4 was indeed the dimerised product of oligomers 12 and 13, 
the products of this ligation were digested with Xba I and 
visualised on a native polyacrylamide gel as shown in Figure 
5. The major band of 38 base pairs is cleaved to give the 
12+13 double-stranded oligomer.
These experiments demonstrate that the oligomers can 
be simply built into larger molecular weight structures. By 
capitalising on the fact that structures will dimerise, can 
be subsequently cleaved around terminal restriction enzyme 
sites and the correctly assembled products thereby, easily 
identified and isolated from high resolution acrylamide 
gels.
3.1.3 First Stage Ligations
Of the twelve oligomers shown in Figure 3, eleven 
were now used in the first stage of the gene assembly. This 
was carried out in four separate reactions in which molar 
equivalents of overlapping oligomers were combined such that 
two particular fragments were ligated whilst held in correct 
alignment by hybridisation to the third, as illustrated in
1 2 3
DEMONSTRATION OF 
DIMERIC ASSEMBLY. 
Xba I  
^  cut.
40 
30
20
-  10
Native.
Figure 5. Cleavage of the dimeric assembly.
Lane 1 shows the dimerisation of oligomers 12 and 13, as 
in Figure 4 . Lane 2 shows the effect of cleavage of this 
by Xba I. Lane 3 shows Hind III linker m.wt. markers.
12+13
12
13
P
2 X
(12+13)
FIRST STAGE
A B C D
2 x (1 2 +1 3)
12+13
I
2 x ( 2 0 + 2 2 + 2 3 )
-40
-30
14+15+17
-20
2 0 + 2 2 + 2 3
-10
N A T I V E .
Figure 6. First stage ligations.
The first stage ligations showing the 4 initial 
sub-assemblies, A,B,C and D. Assembly A comprising 
oligomers 12 and 13 (Lanes 1 and 2); B comprising
oligomers 14,15 and 17 (Lanes 3 and 4);C comprising
oligomers 16,18 and 19 (Lanes 5 and 6);D comprising
oligomers 20,22 and 23 (Lanes 7 and 8). Lane 9 Hind
m.wt. markers (not clearly visible).
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Figure 1. The exception to this is in the ligation of 
oligomers 12 and 13 which was carried out as in the 
pre-assembly stage. The assembly of oligomers 22 and 23 will 
generate a terminal Bam HI site analagous to the Xba I site 
formed by 12 and 13 which likewise facilitates dimerisation.
Figure 6 shows each of these reactions run on a 
native polyacrylamide gel. In each case the major band is 
positioned where the correctly assembled tri-mer would be 
expected with unligated oligomers also clearly visible.
Each of these assembly intermediates was now removed 
in as small a gel slice as possible and extracted from the 
acrylamide by means of electro-elution. Each fragment thus 
isolated can be further verified by electrophoresis on an 
acrylamide/urea denaturing gel as demonstrated in Figure 7.
The importance of the isolation of correctly 
assembled intermediates from the native gel is highlighted 
by the appearance of faint bands running slightly below some 
of the products in Figure 7, especially evident in lane D. 
Whether or not this material would play a significant 
interfering role in the later stages of assembly is 
impossible to say. Clearly its presence along with unligated 
oligomers would be likely to reduce the yield of correctly 
assembled fragments and cloud interpretation of the 
fragments obtained. The exclusion of these fragments is 
therefore of high priority.
3.1.4 Second Stage Ligations
The products of the first stage ligations (A,B,C,D) 
were now subjected to further assembly following the logic 
outlined in Figure 1. Intermediates A and B were combined as 
were C and D along with the linking oligomer 21. Ligations 
were carried out as before and assembled products again 
separated on a 20% poly-acrylamide gel as shown in Figure 8.
PRODUCTS OF 
F I R S T  STAGE LI GATI ON 
AND PURIFICATION.
M
A B C D
12+13 4
15+17
20+22+23
- 6 0
- 5 0
> - 4 0
1 - 3 0
20+22 
•  0 - 2 0
14
19
f
-10
7 M  U R E A
Figure 7. Extracted products of first stage.
The four purified sub-assemblies A(Lane 1); B(Lane 2) 
C(Lane 3) and D(Lane 4), run on a 7M urea, denaturing 
poly-acrylamide gel. Lane 5 Hind III m.wt. markers. 
Single stranded products of first stage ligations are 
indi cated.
S E C O N D  S T A G E
“l i g a t i o n s .
A + B C + D + 2 1
2 x 1 2 - 1 7
,12-17
12+13
12-17 
2 x  12+13
1 4 - 1 7 -
,artefacts-
- 6 0
_ 5 0
_ 4 0
3 0
S8 0 2 x 1 6 - 2 31 6 - 2 3  +  2 0 - 2 3
1 6 - 2 3  and 
2 0 - 2 3 x 2
2 0 - 2 3  + 2 1
12+13
15+17-
20
16+ 1 8
10
Native.
21
Figure 8. Second stage ligations.
Electrophoresis of second stage sub-assemblies on a 20% 
poly-acrylamide gel. Lanes 1-3,assembly A+B. Lanes 
5-7,assembly C+D + oligomer 21. Lane 4, Hind III linkers 
as markers. Oligomers present in each assembly are 
indicated.
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Bands of the expected size were obtained with in each 
case the major assembled band appearing to be the two 
desired fragments A+B and C+21+D. These bands cannot be 
accurately sized using the ladder of molecular weight 
markers but are determined as being the correct fragments 
based on their relative mobility to the other known 
fragments and upon the observation that they are cleaved as 
expected by the respective restriction enzymes Xba I and Bam 
HI as illustrated in Figure 9.
In each case the bands representing fragments 
dimerised about the terminal restriction sites are cleaved 
to give the expected lower molecular weight products such 
that in lane A+B the 2x(12-17) and (12-17+12-13) bands are
cleaved giving fragments 12-17 and 12-13. Similarly in lane
C+D+21 the 2x(16-23) and (16-23+20-23) bands are cleaved to 
give the fragments 16-23 and 20-23. Unfortunately in the 
latter case the material loaded on to the gel following 
cleavage was at lower concentration to that prior to 
cleavage making the bands more difficult to see.
Nevertheless this represents good evidence that the two 
major products in Figure 8 are indeed the correctly 
assembled fragments of the gene. These fragments were now 
recovered taking care to avoid minor contaminants which are
evident running slightly above the major bands.
3.1.5 Final Stage Assembly
The Xba I to Bam HI fragment representing the right 
half or C-terminus of the gene was now arrived at by 
ligation of the two fragments thus derived from the second 
stage of assembly.
1 2 3 4 5
SECOND STAGE 
CLEAVAGES.
A+,B " - *  C+D+21 ^
V Xba I  i  Bam H I
2 * 12-17 O *  A )  2 * 16-23
12-17+12-13 16-23+20-23 • *
M
12-17 t a a  O P  5 0  «  16-23
2 *1 2 -1 3  4( ^  (2*20-23)Cut
l i " 17 20-23+21
20
12+13 —  -  rnjm
15+17 —1
--16+18
14 10
NATIVE.
21
Figure 9. Cleavage of second stage ligations.
Electrophoresis on a 20% poly-acrylamide gel of fragments 
generated upon cleavage of second stage sub-assemblies. 
Lane 1, sub-assembly A+B; Lane 2, cleavage of sub-assembly 
A+B by Xba I; Lane 3, sub-assembly C+D + oligomer 21; Lane 
5, cleavage of sub-assembly C+D + oligomer 21 by Bam HI. 
Lane 4, Hind III linkers as markers.
FINAL
STAGE
UROGASTRONE
C-terminus.
Figure 10. Final stage assembly.
Fragments generated in the final assembly stage of the 
C-terminal half of the gene. Lane A, shows the result of 
ligation of sub-assemblies (A+B) + (C+D +oligomer 21). 
Concatameric multimers ligated about the terminal Xba I 
and Bam HI restriction sites are indicated. Lane B, shows 
Xba I cleavage, and Lane C, Bam HI cleavage of these 
fragments. Lane D shows double cleavage with Xba I and 
Bam HI. The fragment most likely to represent the 
C-terminal fragment of the gene, and a possible dimer and 
intermediate structure, are also indicated.
'A B C T
In! '! tMULTIMERS 'Z H A M  x2x1-5
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Following ligation of these two fragments, a series 
of fragments is expected with incremental size representing 
the concatenation of the dimers about the terminal 
restriction enzyme sites. Cleavage with either of these 
enzymes should yield molecules dimerised about the opposite 
site as well as some monomeric molecules. Simultaneous 
cleavage with both enzymes would be expected to yield
primarily the Xba I to Bam HI fragment. This can be seen to
be the case in Figure 10.
Lane A represents the concatemers formed by ligation 
of the two fragments isolated in Figure 8. In lane B these 
fragments are cleaved with Xba I and in lane C with Bam H I . 
Lane D shows the result of cleavage with both enzymes to 
give what appears to be the desired fragment of the
Urogastrone gene. This fragment was isolated as before and
cloned into the vector pLFl.
The importance of gel purification at each stage of 
the process and particularly at this final stage in the 
series of oligonucleotide assembly reactions is now very 
apparent, since there is only a small percentage of the 
original oligomers present in what is now believed to be the 
correctly constructed fragment of the gene. The presence of 
excess quantities of monomeric or partially assembled 
oligomers would severely interfere with the cloning step, 
into the plasmid vector. This is especially evident with the 
terminal fragments incorporating the restriction sites which 
would be very likely to saturate the ends of the vector 
preventing the incorporation of the C-terminus of the gene 
and possibly necessitating considerable screening of clones.
As it was, of 8 clones screened by restriction 
cleavage with xba I and Bam HI each proved to contain a 
fragment of approximately 88 base pairs, indicative of the 
C-terminus of the 3-urogastrone gene.
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3.2 Cloning of the synthetic gene
3.2.1 Construction of the cloning vector
Subsequent to the isolation of the desired fragment 
of DNA, a plasmid vector was chosen for the cloning step. 
Most work to date involving the cloning of fragments of DNA 
in E .coli has made use of the ColEl derived vector pBR322 
since it is a stable and versatile multi-copy plasmid with 
few occurences of structural instability. The plasmid 
however used in all the cloning stages of the |3-urogastrone 
gene was pATl53, a copy number mutant of pBR322 which 
offered several advantages over the parent plasmid.
Primarily, pATl53 is deleted in the region of the DNA 
containing the origin of transfer, present in pBR322 and 
unlike the former is consequently non-mobilisable. This was 
very relevant at the time of cloning since this work was 
subject to the guidelines of G.M.A.G. and carried out under 
appropriate conditions subject to biological safety 
categorisation. Using a vector which was incapable of 
conjugal transfer contributed to the assignment of category 
1 containment to this work, which greatly assisted in the 
technical ease of manipulations. Furthermore the elevated 
copy number of pATl53 provided additional advantages. Larger 
quantities of plasmid DNA could be more readily isolated and 
genes cloned in the vector, being present in higher numbers 
of copies may be more highly expressed and therefore more 
easily detected, characterised and subsequently purified.
However, pATl53 did not possess a unique restriction 
cleavage site for Xbal, necessary in the cloning of the 
C-terminus of the gene. This site was therefore introduced 
by means of subcloning onto pATl53 a fragment of 
approximately 840 base pairs from a different plasmid,
B a m  HI EcoRI
Bam HIXba  I
Eco Rl
pAT15 3
K m r
^  M ^
1 2 3
/
*
E c o R I
Bam HI
r
I
Ap
Figure 11. Generation of plasmid pLFl.
Following cleavage by Eco RI and Bam HI and agarose gel
electrophoresis, the small fragment of pUBllO (Lane 1) 
was isolated along with the large fragment of pATl53 
(Lane 2). These were ligated to generate plasmid pLFl. 
Lane 3 contains m.wt. markers consisting of a Hind III 
digest of phage lambda and a Hae III digest of phage
<J>X174. (See appendix 2 for fragment sizes).
EcoRI
Xba I
BamHI
pLFl
41 kb
*
+  C-terminus 
UROGASTRONE  
Xba — Bam
I
EcoRI
Xba
BamHI
Figure 12. Cloning of the C-terminal fragment of the 
(3-urogastrone gene.
Following cleavage with Xba I and Bam HI the large 
fragment of pLFl was isolated as shown. This was then 
ligated to the isolated fragment of the p-urogastrone 
gene, giving plasmid pURl.
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pUBllO as shown in Figure 11. Plasmid pUBllO was originally 
isolated from Staphylococcus aureus and is as yet relatively 
poorly characterised. A partial restriction map is however 
available and the plasmid is known to carry resistance to 
kanamycin. This is not located on or near the fragment 
subcloned into pATl53, which did not confer any obvious 
novel phenotype nor show any structural instability when 
propagated in E .coli.
Each plasmid was cleaved with EcoRI and BamHI and the 
appropriate fragments (as arrowed) extracted by 
electro-elution from a 1% agarose gel. The resultant plasmid 
pLFl when cleaved with Xba I and Bam HI could then be used 
for the cloning of the |3-urogastrone fragment, as 
illustrated in Figure 12.
3.2.2 Analysis of C-terminal clones of (3-urogastrone
Following transformation of competent HB101 with pLFl 
cleaved as in Figure 12 and ligated to the extracted 
fragment of the |3-urogastrone gene, 24 colonies were 
isolated of which eight were subjected to initial 
restriction analysis.
The insert was entirely excised as well as being 
cleaved with each of the enzymes designed to be present in 
the correctly assembled fragment. Part of this analysis is 
presented in Figure 13. Each of four clones can be seen to 
liberate an identical fragment of around the expected size 
of 88 base pairs (A) upon cleavage with Bam HI and Xba I. 
Each also contains an additional Hae II site not present in 
the vector pLFl but which maps at the predicted position in 
the gene, cleaving the largest vector fragment to yield
an additional 77 base pair fragment (B). Further cleavage 
with enzymes Fnud II and Hph I yielded the fragments 
expected from cleavage of the sites in the 3-urogastrone 
gene. Since these cleavages strongly suggested that the
Figure 13. Identification of pURl.
Restriction analysis of four putative pURl isolates.
Lane 1; pLFl cleaved by Xba I and Bam HI. Lanes 2-5; 
isolates 1-4 cleaved by Xba I and Bam HI. Lane 6; m.wt. 
markers <J>X174 rf DNA cleaved by Hae III. Lanes 7-10; 
isolates 1-4 cleaved by Hae II Lane 11; pLFl cleaved by 
Hae II. The 88bp fragment of the |3-urogastrone gene is
arrowed (A), in lanes 2-5. The 77bp additional Hae II
fragment, due to the extra site present within the
3-urogastrone gene is also arrowed (B).
GAATT CC 
CTTAA GG
AAGCTT
TTCGAAJ
GG A A T T C 
CC TTAAG
EcoRI
Xba I
BamHI
\
Hind III
EcoRIEcoRI
BamHI
p U R 2
3'86kb
Figure 14. Generation of plasmid pUR2.
The sequence of the Hind III linker inserted at the 
unique Eco RI site of plasmid pURl is shown at the top 
The restriction sites present in the resulting plasmid 
pUR2 are shown at the bottom.
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correct fragment had been cloned, one of these isolates 
designated pURl was prepared for the cloning of the 
N-terminus of the gene.
3.2.3 Construction of pUR2
The fully assembled N-terminus of the gene was 
flanked by restriction sites for Hind III and xba I 
necessitating the presence of unique targets for these 
enzymes in the cloning vehicle. A Hind III site was 
therefore introduced at the unique Eco RI site of pURl by 
means of linker insertion. The sequence of the linker was 
such that it reconstituted the Eco RI site on either side as 
diagrammed in Figure 14. Subsequent cleavage with Hind III 
and Xba I yielded the necessary vector for cloning of the 
fragment encoding the N-terminus of 0-urogastrone. This was 
designated pUR2.
3.2.4 Cloning of the N-terminal fragment and analysis of 
the full gene
The N-terminal fragment of the gene was assembled 
using essentially the same methodology as outlined for the 
C-terminus. It was then ligated to the purified large 
plasmid fragment obtained from Xba I and Hind III cleavage 
of pUR2, as illustrated in Figure 15.
Five isolates were prepared and cleaved with enzymes 
Hind III and Bam HI. As shown in Figure 16, one released a 
fragment of the approximate size to be the p-urogastrone 
gene. This fragment was extracted and cloned into M13 
vectors mp8 and mp9 in which the total nucleotide sequence 
of the gene was determined on each strand. The sequence 
obtained, as shown in Figure 17 was exactly that of the 
correctly assembled oligomers of the synthetic gene.
EcoR
Xba
BamHI
PUR 2
+
N-terminus
U R O G A S T R O N E
Xba I
Hind IIIEcoRI
Bam HI
PUR 3
3HEH
Hindlll ____________ »____________  Bam HI
B -U R O G A STR O N E G E N E.
Figure 15. Cloning strategy for the N-terminal fragment 
of the ft-urogastrone gene.
The large fragment of plasmid pUR2, as illustrated at 
the top, was isolated following cleavage by Hind III and 
Xba I. This was ligated to the assembled N-terminus of 
the gene yielding the full length insert.
Figure 16. Identification of pUR3.
Restriction of five putative p U R 3 isolates. Lanes 1 and 
7; m.wt. markers <})X174 rf cleaved by Hae III. Lanes 2-6 
five isolates cleaved by Hind III and Bam HI. Lane 5 
(isolate 4), contains a fragment of the approximate siz 
of the |3-urogastrone gene (174bp), as arrowed (A). This 
migrates slightly below the 194bp band of the m.wt. 
markers.
Figure 17. Sequence of the cloned (3-urogastrone gene.
Sequence of both strands of the 0-urogastrone gene. The 
gene was cloned between the Hind III and Bam HI sites of 
M13 vectors mp8 and mp9 and sequenced in both directions 
using universal sequencing primer (Biolabs). Track A 
reads from the Hind III (H) site at the bottom towards 
the Bam HI (B) site at the top. Track B reads from the 
Bam HI (B ') site at the bottom towards the Hind III (H') 
site at the top. Sequence lanes in both cases are in the 
order A.G.C.T. Sequence at the top of the gel was 
discerned by extended electrophoresis. Chevrons indicate 
the point of overlap between the gels.
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3.2.5 Discussion
These results demonstrate the feasibility of total 
gene synthesis as a means to the cloning of a DNA sequence 
encoding a given peptide. At the time of assembly the 
urogastrone gene was the largest synthetic gene to have been 
cloned although subsequently several larger genes have been 
cloned, both in these laboratories and in others (95). The 
methodology employed however, has in many cases been closely 
based upon strategies used or developed in this work. Much 
of this strategy is self-evident although it is important to 
stress the relevance of several factors carefully considered 
in this work. Primarily, it is important to consider in 
detail the logic of the gene assembly and the eventual 
destination of the gene for expression, in the specific 
incorporation of restriction sites. The identification of 
sequence sub-assemblies and the subsequent versatility of 
the gene for manipulation are greatly facilitated by 
incorporation of useful sites. The systematic purification 
of sub-assemblies significantly reduces the possibility of 
eventual cloning of wrongly ligated material or the 
saturation of cloning vector restriction ends with high 
concentrations of unligated monomer. Finally the usefulness 
of computer assistance cannot be over-stressed. The programs 
used in the elimination of repeating structures in this work 
avoided time-consuming comparisons by eye and have now been 
superseded by more sophisticated and more rapid programs. 
This underlines the dynamic nature of this sort of approach, 
since the improvement of computer assistance and indeed of 
gene synthesis now allow faster and more thorough design of 
much larger oligonucleotides. Synthetic genes can now be 
assembled from fragments of 30 to 40 nucleotides in length 
of purity equal or greater to those used in this work. 
Considering the similar progression which is occuring in the 
efficiency of automated protein sequence determination, the 
prospect of gene synthesis becoming the major source of 
cloned DNA is becoming increasingly likely.
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CHAPTER 4
EXPRESSION OF g-UROGASTRONE IN E.coli
USING trp PROMOTER REGULATED EXPRESSION VECTORS
pWT 221-uro
trp E pWT 221 modified Uro Urogastrone
R.B.S. trp E N-terminus Linker sequence.
GAGAATAACAATG CAA ACA CAA AAA CCG ACT TCA AGC TCC AAG CTT AAA AAG AAT TCC GAT 
M Q T Q K P T S S S K L K K N S D
pWT 571-uro
-35 -10
ic'k'k'k'k'k
Attenuator
peptide R.B.S. Urogastrone 
Sequence.
TTGACAATTAATCATCGAACTAGTTAACTAGTACGCAAGTTCACGTAAAAAGGGTATCGACAATG AAT TCC GAT
M N S D
Figure 18. Plasmids pWT221-URO and pWT571-URO.
The DNA and amino acid sequences at the N-terminus of 
(3-urogastrone in pWT221-URO and pWT571-URO.
Hpo t . ------------------------206 b p ---------------------------------------
Trp E SEQUENCE
 353 bp — ------------- y B o m H I
P0R322 Tc REGION
M*t Gin Thr Gin Lys Pro Thr s*r S *r Ser Lys L»u Gly Alo L*u M«l
ATG. CAA. ACA. CAA. AAA. CCG. ACT. TCA.AGC. TCC. a [a G. CTT. GGA. GCT. TTA. ATG.
TAC. GTT. TGT. GTT. TTT GGC TGA. AGT. TCG. AGG. TTC. Ga|a. CCT CGA. AAT. TAC.
Hpa I
Pst 1
Bam HI
353bp FRAGMENT 
REPLACED BV THE 
17* bp SYNTHETIC 
GENE
§ol I
SYNTHETIC 0 -  UROGASTRONE I7*bp
S3 Bom HI
Arg STOP .
AGA TAA. g|
TC T. ATT CCT. Ag |
I L»u Lys Lys Asn Sor Asp S«t Glu 
AG. CTT. AAA. AAG. AAT TCC. GAT. AGC. GAG.
THE FUSION SEQUENCE ... _ „  TRYPSIN CLEAVAGE
M lMr» Gin Thr Gin Lys Pro Thr S*f S*r S«r Lys L«xj L y sF L y s ' Asn
ATG. CAA ACA CAA. AAA CCG. ACT TCA AGC TCC. a |*G. CTT AAA AAG. AAT
TAC GTT TGT GTT TTT GGC TGA AGT TCG AGG TTC. Ga|a . TTT TTC TTA
Figure 19, Derivation of plasmid pWT 221-URO,
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4.1 Plasmid Construction
Following total DNA sequencing the (3-Urogastrone gene 
was cloned into expression plasmids containing the promoter 
and operator regions of the tryptophan (trp) biosynthetic 
operon of E .coli K12. These were obtained from Dr W.Tacon at 
G.D.Searle. Two plasmids were constructed in which 
0-Urogastrone could be expressed either as a mature peptide 
or incorporating a 14 residue N-terminal fusion as shown in 
Figure 18. This fusion comprised the 4 residue linker region 
preceded by the first 10 residues of the Trp E protein, 
anthranilate synthase.
Plasmid 221-URO was formed by ligating the 174 bp 
Hind III to Bam HI fragment encoding (3-urogastrone form pUR3 
into the similarly cleaved expression plasmid pWT221 as 
shown in Figure 19. Plasmid 571-URO was constructed by 
ligating the 163 bp Eco RI to Bam HI fragment of the 
(3-urogastrone gene also from pUR3 into similarly cleaved 
pWT571. This expression vector lacks the attenuator region 
of the trp promoter, originally being designed to potentiate 
greater transcription rates than the wild type promoter in 
the presence of low levels of tryptophan. The plasmid was 
constructed using a specific linker region incorporating an 
Eco RI site at the beginning of the attenuator polypeptide 
coding sequence. This allows expression of mature 
(3-Urogastrone inserted at this position using the 
translation initiation point of the trp attenuator 
polypeptide.
Plasmid ligations were transformed into host HB101 
and correctly assembled plasmids identified in each case by 
restriction cleavage. Copy numbers of both plasmids were 
determined at approximately 100 per cell.
Graph 1. Expression of Trp E fused urogastrone Ln HB1Q1.
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Table 1
Sample ND ND ND ND 1 2 3 4 5 6 7 8
Time 0 60 90 120 150 165 210 240 270 300 330 390
A 600 0-1 015 0-21 0-36 052 0 66 0-63 103 1-78 2-2 2-48 2 82
ng.uro/ml 
To A&oo 
R .l.A .
- - - - 39-6 151-5 298-7 286-8 161-7 101-8 1116 22 6
ng uro/ml 
to A 10 
R.B.A.
- - - - 0 87-2 125 3 170-5 155 1436 74-5 23
Graph 1. and Table 1.
Expression of Trp E fused urogastrone in HB101, as 
detected by receptor binding and radio-immuno assay.
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4.2 Expression of p-urogastrone
4.2.1 p-urogastrone expression in HB101
The expression of p-Urogastrone in HB101 using these
vectors was now examined by two forms of biological assay.
Firstly in a receptor binding assay, p-urogastrone in
125bacterial extracts was used to compete against I labelled 
urine derived p-urogastrone for EGF cell surface receptors 
on cultured fibroblasts. It was also measured using a 
radio-immuno assay employing antiserum isolated from rabbits 
immunised with conventionally isolated human p-Urogastrone. 
Expression of Trp E fused urogastrone was measured using 
both forms of assay but mature p-Urogastrone was assayed 
initially by radio-immuno assay only, due to technical 
problems with the receptor binding assay. Expression of both 
mature and Trp E fused urogastrone was induced by the 
addition of 3 g-indole acrylic acid and the expression 
levels measured before and after induction. Following 
induction, p-urogastrone expression was measured throughout 
the exponential and early stationary growth phases of HB101. 
Cell growth and the presence of Trp E fused urogastrone 
during this time are shown in Table 1 and plotted on Graph 
1. All samples of control cultures of HB101 alone showed no 
detectable activity within the range of both forms of assay.
4.2.2 p-urogastrone expression in a protease deficient host 
strain
To examine the possible effect of proteolytic 
degradation of p-urogastrone, the expression of plasmid pWT 
571-URO was examined in host HW27 which is an E.coli K12 
derivative defective in the Ion gene. The product of the Ion 
gene is an ATP dependent protease and genetic studies have 
shown that mutants in this gene have a reduced capacity to 
degrade abnormal proteins (96). Cell growth and the presence 
of native p-urogastrone as detected by radio-immuno assay
Graph 2. Expression of native B~uroqasirone In HB101 and HW27.
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Table 2
Sample ND ND 1 2 3 4 5 6 7 8
Time 0 60 120 150 180 210 270 330 390 450
H B 101 
A 600
0 1 0-17 o-;o5 0-5 0-71 096 1-63 2-1 2-45 2-79
HB 101
n g .u ro /m l  
t0 A600 1-0
- - 13B 310 207 243 174 129 101 40-8
WW 27 
A 600
0-1 017 0-39 0-52 0-77 1-03 1-95 2 4-3 2 79 2-94
HW 27 
ng.uro/ml
to A6oo1 0
- - 123 353 356 424 333 330 347 205
Graph 2. and Table 2.
Expression of native g-urogastrone in HB101 and HW27 as 
detected by radio-immuno assay.
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were monitored throughout exponential and early stationary 
phases and are shown in Table and Graph 2. A culture of HW27 
alone showed no detectable activity within the range of 
either assay.
4.2.3 Discussion
Clearly the synthetic gene is expressed from the trp 
promoter in both plasmid constructions, and both forms of 
the peptide molecule are synthesised in HB101. Following 
induction of both Trp E fused and mature g-urogastrone, 
there is a rapid increase in intracellular levels. These are 
maintained between 100-300 ng/ml as detected by radio-immuno 
assay throughout the exponential growth phase. These initial 
experiments have since been extensively repeated (E.Cook 
personal communication) indicating similar expression levels 
of Trp E fused and mature g-urogastrone to those observed 
here. Levels drop considerably as the cells enter stationary 
phase, most likely due to an increase in proteolytic 
degradation as protein turnover is markedly increased at 
this stage in the growth of E .coli. In addition, other 
heterologous peptides have been shown to induce proteolysis 
during their expression in E .coli (102). The susceptibility 
of g-urogastrone to proteolytic degradation is further 
indicated by the fact that higher levels of the peptide are 
detected throughout growth in the Ion strain HW27. It is 
also indicated by the fact that higher levels of Trp E fused 
urogastrone are detected by the radio-immuno assay which may 
detect partially degraded or unfolded protein than by the 
receptor binding assay which most likely requires the intact 
and correctly folded molecule. It should however be stressed 
that although g-urogastrone activity is assumed, the 
biological assay used here, only measures the EGF activity 
of the peptide. It is conceivable although unlikely that 
some partially degraded material retains EGF activity whilst 
having lost g-urogastrone activity.
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Following these experiments a considerable programme 
of work was initiated both to increase the expression levels 
of p-urogastrone in E .coli and to study the turnover of the 
peptide. Plasmids of copy number elevated above that of 
pATl53 and incorporating tandem trp promoter regions have 
been used to give levels of 2-3ug of mature and Trp E fused 
urogastrone per ml of cells (A^qq 1.0) (T.Smith personal 
communication). Pulse labelling has also shown the half-life 
of mature 3-urogastrone in E .coli to be about 2 minutes and 
of Trp E fused urogastrone to be 5 minutes (M.Carrier 
personal communication). The activity of Trp E fused 
urogastrone has also been shown to be identical to the 
native molecule and the trypsin labile site within the 
linker region can be effectively cleaved without affecting 
the other trypsin cleavage sites of the peptide. These are 
most likely to be folded within the molecule and therefore 
inaccessible to the enzyme.
The preliminary results presented in this work 
however do illustrate the potential, assuming a recovery of 
50% to isolate from a 201 fermentation the equivalent active 
protein formerly requiring 10001 of urine. Given the 
improvements discussed above that potential may be 
considerably greater.
However if sufficient material was to be isolated to 
allow investigation of its possible therapeutic potential 
and to allow detailed study of the molecule, large 
quantities would be required. Should the rapid proteolysis 
remain a significant factor or if problems were encountered 
with purification then alternative hosts to E .coli might 
have to be considered. In particularly an organism which 
unlike E .coli might alleviate these problems by secretion of 
the peptide. The feasibility of an alternative host to 
E .coli for the expression of 3-urogastrone was therefore
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examined. Since bacilli have been extensively used in 
industrial fermentation (as discussed in Chapter 1) and have 
the capacity to secrete large quantities of protein, a 
system was designed for the expression initially of 
(3-urogastrone and potentially of subsequent peptides in 
bacilli. In addition, since B .subtilis is the best 
characterised of the bacilli and has been a subject of very 
recent interest the system was designed with B.subtilis as 
the initial host but with the potential for the transfer to 
alternative bacilli. Following a study of the comparative 
regulation of gene expression in B .subtilis and E .coli a 
series of vectors were then designed.
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CHAPTER 5 
DESIGN OF A SYSTEM FOR 
GENE EXPRESSION IN B.subtilis
1 2 3 4 5 6 7 8
n ;; h r
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Figure 20. Identification of pFF2.
Restriction analysis of putative pFF2 isolates. Lanes 1 
and 8; m.wt. markers <f>Xl74 rf DNA cleaved by Hae III. 
Lanes 2-6; five isolates cleaved by Eco RI, Bam HI and 
Bgl II. Lane 7; pATl53 cleaved by Eco RI and Bam HI as an 
additional m.wt. marker. Lanes 3 5 and 6 (isolates 2,4 
and 5), contain the expected fragments of the correctly 
ligated plasmid. Lanes 2 and 4 contain incorrectly 
assembled plasmids.
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5.1 Design of the expression vectors
5.1.1 Design of the shuttle vector
Primarily a dual replicon or shuttle vector was 
designed as a precursor to potential expression vectors.
This plasmid was intended to be capable of selectable 
propagation in both E .coli and B .subtilis in order to 
facilitate DNA manipulation steps in the more easily handled 
E.coli with subsequent transformation of B .subtilis for 
expression studies. Plasmid pATl53 was chosen as the E .coli 
replicon since it had been successfully used in all previous 
cloning experiments of this work. Plasmid pUBllO was chosen 
as the B .subtilis replicon as it had been previously used 
quite successfully in dual replicon plasmids (55), and had 
covenient situation of restriction sites for ligation to 
pATl53. Furthermore it had already been handled in this 
work, proving useful in the generation of pLFl for the 
cloning of the p-urogastrone gene.
5.1.2 Construction of the shuttle vector
Both plasmids were cleaved with enzymes Eco RI and 
Bam HI and the larger fragments electroeluted from 1% 
agarose gels, following staining with ethidium bromide and 
visualisation under long wave UV irradiation. These 
fragments are represented by the larger fragments in lanes 1 
and 3 of Figure 11. They were then ligated, transformed into 
HB101 and ampicillin resistant colonies selected. Of 5 
colonies streaked onto L-agar plates containing 5ug/ml 
kanamycin, only 3 proved to be resistant and grew. Plasmid 
DNA was prepared from all five and restricted with Eco R I , 
Bam HI and Bgl II. The correctly ligated vector should show 
cleavage fragments of 3.28kb, 1.5kb and 2.2kb since the 
pATl53 fragment is excised intact and the pUBllO fragment is 
cleaved at the single Bgl II site approximately 1.5kb from 
the Bam HI site. Figure 20 shows that clones 2,4 and 5 (all 
kanr) show these fragments and that the others are
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incorrectly ligated. Clone 2 was designated pFF2 and stored 
as a glycerol stock. Plasmid DNA was then prepared for 
cloning of the SPPl fragment.
5.1.3 Cloning and sequencing of Eco RI fragment 10 of SPPl
Total digestion of B .subtilis phage SPPl genome with 
the restriction endonuclease EcoRI produces 15 fragments, 
ranging approximately from 350 bp to 7.6 Kb in length (97). 
The 1.4 kb fragment 10 carries one of the five major early 
promoters of the phage genome (73). As mentioned this 
promoter is efficiently transcribed both in vivo and in 
vitro. Fragment 10 of the SPPl genome was kindly supplied by 
Dr.T.Trautner at the Max-Planck Institute in Berlin. This 
fragment was cloned into the unique Eco RI site of shuttle 
vector pFF2 and further plasmid manipulations carried out as 
shown in Figure 21. Clones were isolated containing the 
fragment in either orientation as determined by cleavage 
both at the unique Xba I site asymmetrically placed within 
the fragment and at the single Pst I site in pATl53. The 
desired orientation was that in which transcription 
proceeded towards the pATl53 replicon as depicted. This 
plasmid was named pFF4. In order to facilitate further 
plasmid constructions the upstream Eco RI cleavage site was 
destroyed by partial digestion with Eco RI followed by 
nuclease Si treatment and blunt end ligation. This resulted 
in the vector pFF401.
This vector provided both the precursor for the 
plasmids which were subsequently used to study urogastrone 
expression plus a source of the SPPl promoter for DNA 
sequence analysis and transcription mapping. Several 
restriction enzymes were then tested for the presence of 
cleavage sites within the SPPl fragment. Cleavage with the 
enzyme Pvu II revealed a single site within the fragment 
approximately 500 bp upstream of the Eco RI site of pFF401. 
Since the promoter had been roughly approximated to be close
1 50 100 150 200 250 300 350 400 450 499
U n i versal. >
2nd Primer. ------------------------------------ >
3rd Primer --------------- >
5' 3*
«---- I------1----- 1----- 1----- 1----- 1----- 1----- 1----- 1----- 1«--- 1---- 1----1----1----1----1----1----1----1----1
3' 5'
<----------------------3rd Primer
<--------------------------------- 2nd Primer
Universal.
Figure 22. Sequencing strategy for the 499bp SPPl 
f ragment.
1 2 3 4 5 6
Figure 23. Sequence analysis of the 499bp SPPl fragment.
Tracks 1-3; top strand universal primer, 2nd primer, 3rd 
primer. Tracks 4-6; bottom strand universal primer, 2nd 
primer, 3rd primer. All tracks contain sequence lanes in 
the order A.G.C.T. The position on either strand of the 
Eco RI site (E) and Pvu II site (P) are indicated.
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to this Eco RI site it seemed likely that it would be 
incorporated within the 500bp Pvu II to Eco RI fragment. 
Double cleavage with these enzymes released this fragment, 
which was then cloned into the M13 derived, phage vectors 
mp8 and mp9, each cleaved with Eco RI and with Sma I. Since 
DNA fragments cleaved with Pvu II and Sma I possess blunt 
ends they may be ligated together. The sequence of this 
fragment was then determined on both strands by means of the 
dideoxy chain termination method of DNA sequencing. After 
sequencing of the fragment termini, four additional specific 
sequencing primers were designed to facilitate the 
completion of sequencing of the entire fragment, as shown in 
Figure 22. Part of this analysis is shown in Figure 23 and 
the entire sequence of the fragment along with the position 
of known restriction endonuclease sites shown in Figure 24.
5.1.4 Analysis of the SPPl fragment
Only two open reading frames capable of encoding a 
peptide larger than 40 residues are present. The larger of 
these initiates with an ATG codon at base 266 and continues 
to the end of the fragment, potentially encoding a peptide 
of at least 78 residues. This is preceded by a region 
strongly characteristic of a B .subtilis ribosome binding 
site, incorporating the highly conserved sequence 5' GGAGG 
3' positioned seven bases prior to the potential ATG start. 
The other open frame initiates with an ATG codon at position 
96 and terminates with a TAG stop codon overlapping the S.D. 
box of the second open frame, potentially encoding a peptide 
of 52 residues. This is preceded by a region less 
characteristic of a B .subtilis ribosome binding site but 
which nevertheless possesses homology to the 3' end of the 
16S subunit of rRNA. It is not known which gene products are 
expressed from the promoter at this region of the SPPl 
genome although two peptides of around 50 and 75 amino acids 
in length have been detected in E .coli minicells carrying 
the 1.4 kB SPPl fragment cloned onto pBR322 (76). The
A
CAGCTGAATGAAAAATATTCATCTTTTTTTAAAAATAGTGGTTGCCTTTCTATGTTTTCTATGTTTTAATAG
AATCATAGAGAGGGGGGGACAAOVTGAACGAGCAAAAGAGAGTTAAGAAAAACCTTGAAGTAAGCCCGACAG
TGTGGAAGAAAGCTCACATCATGAAGGCTGACACAGGCAAGAAACTCTATGAAATTTTAGAAGAAGCAATCA
ACGAAATGTATGAGCGGCACGAGCCGAAACACTTTTAGGAGGGGTTAAAATGGCGAGGGTAGTGGCAAACAC
GAAGGACATGCCACATGAGGAATGGTTGGCACTTCGTAAGCACGGCATTGGCGGCAGTGATGCGGCAAAGGT
GTTAGGAGTCAGCAAATACGGTAGCCCGTTAACAGCTTACATGGAGAAGAAAGGAATGTACACCCCGAAAGT
TAGCGAAGCGACGGAAGAAGCCGCTAGGTGGGGGACGATCATGGAGCCAGTTCTTCGGGACGAATTC
B
SPPl. Pvu II - Eco RI 499 bp fragment.
83 166
Enzyme 
Aha III 
Alu I 
Dpn I 
Dra I 
EcoRI 
Fnu4H I 
HinC II 
HinF I
Hpa
Mbo
No. Cuts +- 
1. 
3.1 
1.
1.
1.
4.
1.
.
1.
1.
5.
4.
6.
Mbo II 
Mnl I 
Nla III 
Nla IV 
Pvu II 
Rsa I 
Sau3A I 
SfaN I 
Tthill II
19 enzymes found
.1
250 333 416 499
— !-------!------ 1------ >
11 1 
11
11 1 
1
1
1
1
1 11
1 1 
1
Figure 24. DNA sequence and restricion map of the 499bp 
SPPl Pvu II-Eco RI fragment.
The 499bp sequence of the Pvu II to Eco RI fragment of 
the SPPl genome is shown at the top (A). The approximate 
position of known restriction endonuclease sites within 
the fragment is shown below (B).
SPPl. PVU II to ECO RI FRAGMENT 
TRANSCRIPTION START POINT AND MAJOR 
OPEN READING FRAMES
-35 Box 17 bases
(-A) (+T) ******<-----------
CAGCTGAATGAAAAATATTCATCTTTTTTTAAAAATAGTGGTTGCCTTTCTATGTTTTCT 
10 20 30 40 50 60
mRNA
-10 Box start R.B.S. (a)
 >****** * **** M N E Q K R V K
ATGTTTTAATAGAATCATAGAGAGGGGGGGACAACATGAACGAGCAAAAGAGAGTTAAGA 
70 80 90 100 110 120
K N L E V S P T V W R K A H I M K A D T
AAAACCTTGAAGTAAGCCCGACAGTGTGGAAGAAAGCTCACATCATGAAGGCTGACACAG
130 140 (TGT)150 160 170(-T) (-AG)
180
G K K L Y E I  L E E A X N E M Y E R H E  
GCAAGAAACTCTATGAAATTTTAGAAGAAGCAATCAACGAAATGTATGAGCGGCACGAGC 
190 200 210 220 230 240
R.B.S. (b)
*****
P K H F ter M A R V V A N T  R D M P
CGAAACACTTTTAGGAGGGGTTAAAATGGCGAGGGTAGTGGCAAACACGAAGGACATGCC 
(TC) 260 270 (—A) (—A) 300
250 280 290
H E E W L A L R R H G I G G S D A A R V  
ACATGAGGAATGGTTGGCACTTCGTAAGCACGGCATTGGCGGCAGTGATGCGGCAAAGGT 
310 320 330 340 <+G) 360
350
L G V S K Y G S P L T A Y M E K K G M Y  
GTTAGGAGTCAGCAAATACGGTAGCCCGTTAACAGCTTACATGGAGAAGAAAGGAATGTA 
370 380 390 400 (C) 410 420
T P K V S E A T E E A A R W G T I M E P  
CACCCCGAAAGTTAGCGAAGCGACGGAAGAAGCCGCTAGGTGGGGGACGATCATGGAGCC 
430 440 450 460 (+T +T) 480
470
V L R D E F 
AGTTCTTCGGGACGAATTC 
490 499
Figure 25. Characterisation of the 499bp SPPl fragment.
The DNA sequence of the Pvu II to Eco RI fragment showing 
the promoter region and potential peptides arising from 
open reading frames greater than 40 amino acid residues 
in length. Sequence differences of Tailor et al (see 
text) are shown in brackets above or below the DNA 
sequence. Deletions are indicated by (-) and insertions 
by.(+) below the preceding base. The -10 and -35 regions 
and the transcription initiation point are indicated by 
asterisks. The two putative ribosome binding sites 
(R.B.S. (a) and (b)) are also shown by asterisks.
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position and sequence of the potential peptides which would 
be encoded by these open reading frames are shown in Figure 
25.
The 499 bp DNA sequence was then subjected to 
statistical computer analysis to examine the likelyhood that 
these open frames do encode peptides (98). This involved the 
determination of di and tri-nucleotide frequencies for 
specific codons in each possible frame. Due to the frequency 
of occurence of particular amino acids, coding regions of 
DNA unlike non-coding regions display a preferential use of 
particular nucleotide combinations independent of any effect 
of codon usage. It is possible within a given sequence to 
measure these frequencies in every frame and to search for 
the presence of this bias. A value or score can then be 
assigned at every position in the sequence for each frame. A 
sequence which consistently scores highest along ah open 
reading frame indicates strong similarity in nucleotide 
content to known coding regions and suggests that the open 
frame does encode a peptide.
As shown in Figure 26, the first of the two major 
open frames within the SPPl fragment scores highly by this 
analysis along its entirety. The second open frame although 
not consistently scoring as highly as the first, 
nevertheless also indicates strong similarity as measured by 
this method to known coding regions of DNA.
The amino acid composition and codon usage of the 
potential peptides were also examined and compared to the 
typical usage in proteins of E .coli and B.subtilis. These 
showed no obvious major differences, except for the fact 
that both of these peptides would be very rich in charged 
amino-acids. The amino acids and codons present are shown in
fr 1
• r..t.i..-... ..................... 1 1 . i '• 1
rbs
fr 2
.• I I ' •••. 1 1 1 •'........................ ..
rbs 1
fr3
. ...  II i i i i /I-- i. i i |.' " i ' ' ’ .
- P , I I1.. 1 1
P
. ......... h i i -11-. >1- ... . . 1 , 1,
Figure 26. Statistical computer analysis of the SPPl 
Pvu II to Eco RI fragment.
For each of the three reading frames (frl, fr2, fr3), 
the scores attained for positional base preference are 
indicated by a point, above or below the centre line of 
each of the top three boxes. The frame scoring highest 
is indicated by an additional point on the centre line 
of the box. Scores are indicated at 3bp intervals. Stop 
codons are shown by a small vertical line on the centre 
line. Potential initiation codons (ATG only), are shown 
by a point along the bottom of each box. Regions showing 
strong homology to E .coli ribosome binding sites are 
indicated by a vertical line at the bottom of each box, 
and are labelled (rbs). The bottom box (P), indicates 
regions displaying homology to the conserved -10 and -35 
hexamers of E .coli promoters. The box above (<->P) shows 
this analysis corrected for appropriate hexamer spacing.
AMINO ACID COMPOSITION AND CODON USAGE
OF FIRST OPEN READING FRAME
1 uuu Phe 0 UCU Ser 2 UAU Tyr 0 UGU Cys
0 uuc Phe 0 UCC Ser 0 UAC Tyr 0 UGC Cys
1 UUA Leu 0 UCA Ser 0 UAA *** 0 UGA ***
0 UUG Leu 0 UCG Ser 0 UAG *** 1 UGG Trp
1 CUU Leu 0 ecu Pro 0 CAU His 0 CGU Arg
1 cue Leu 0 CCC Pro 3 CAC His 0 CGC Arg
0 CUA Leu 0 CCA Pro 1 CAA Gin 0 CGA Arg
0 CUG Leu 2 CCG Pro 0 CAG Gin 1 CGG Arg
1 AUU H e 0 ACU Thr 0 AAU Asn 0 AGU Ser
2 AUC lie 0 ACC Thr 3 AAC Asn 1 AGC Ser
0 AUA lie 2 ACA Thr 4 AAA Lys 1 AGA Arg
3 AUG Met 0 ACG Thr 5 AAG Lys 0 AGG Arg
1 GUU Val 2 GCU Ala 0 GAU Asp 0 GGU Gly
0 GUC Val 0 GCC Ala 1 GAC Asp 1 GGC Gly
1 GUA Val 1 GCA Ala 5 GAA Glu 0 GGA Gly
1 GUG Val 0 GCG Ala 3 GAG Glu 0 GGG Gly
AMINO ACID COMPOSITION AND CODON USAGE 
OF SECOND OPEN READING FRAME.
0 UUU Phe 0 UCU Ser
1 UUC Phe 0 UCC Ser
2 UUA Leu 0 UCA Ser
1 UUG Leu 0 UCG Ser
2 CUU Leu 0 ecu Pro
0 cue Leu 0 CCC Pro
0 CUA Leu 2 CCA Pro
0 CUG Leu 2 CCG Pro
1 AUU lie 0 ACU. Thr
1 AUC lie 1 ACC Thr
0 AUA lie 1 ACA Thr
5 AUG Met 3 ACG Thr
2 GUU Val 2 GCU Ala
1 GUC Val 1 GCC Ala
1 GUA Val 3 GCA Ala
2 GUG Val 3 GCG Ala
0 UAU Tyr 0 UGU Cys
3 UAC Tyr 0 UGC Cys
0 UAA *** 0 UGA ***
0 UAG *** 2 UGG Trp
1 CAU His 1 CGU Arg
1 CAC His 0 CGC Arg
0 CAA Gin 0 CGA Arg
0 CAG Gin 1 CGG Arg
0 AAU Asn 1 AGU Ser
1 AAC Asn 3 AGC Ser
3 AAA Lys 0 AGA Arg
4 AAG Lys 2 AGG Arg
1 GAU Asp 1 GGU Gly
2 GAC Asp 3 GGC Gly
5 GAA Glu 2 GGA Gly
3 GAG Glu 1 GGG Gly
Figure 27. Amino acid content and codon usage of the 
potential peptides from both major open reading frames of 
the 499bp SPPl fragment.
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Figure 27. A search of the NBRF database revealed no 
significant homology of either of these potential peptides 
to any known sequences.
5.1.5 Position of transcription initiation
To determine whether either or both of these putative 
peptides were encoded within transcripts originating in this 
region of the genome it was now necessary to determine the 
position of the SPPl promoter and the exact position of 
transcripton initiation. This was determined by means of 
reverse run-off transcripts initiated on mRNA using specific 
oligonucleotide primers. This was carried out on mRNA 
isolated from both B .subtilis and E .coli containing the 
cloned 1.4 kB fragment on plasmids pFF71 and pFF710 
respectively. Prior to this however the 499 bp DNA sequence 
was subjected to a further computer analysis which searched 
for sequences homologous to the consensus hexamers found at 
-10 (TATAAT) and -35 bp (TTGACA) from E .coli transcription 
start sites. This is useful in allowing predictions of the 
position at which to prime DNA synthesis for run-off 
experiments in order to obtain conveniently sized reverse 
transcripts. The result of this analysis is shown in Figure 
26.
It is very likely that all SPPl early promoters are 
transcribed by the cr43 major form of the B . subtilis RNA 
polymerase. Since all cr43 promoter sites display strong 
homology to these consensus sequences found in E.coli it was 
likely that this form of analysis would detect the location 
of the promoter if it was present on this fragment. The 
content of any homologous hexamers as well as correct 
spacing are measured in this analysis. Using both of these 
criteria a single site was determined within this fragment 
which displayed strong homology to known promoter regions of 
E .coli and B .subtilis. This is illustrated in Figure 25. The 
-35 and -10 hexamers of this potential promoter site were
AGCTR
Figure 28. Initiation point of transcription by E.coli 
RNA polymerase from the SPPl promoter.
Sequence lanes as indicated are in the order A.G.C.T. A 
single reverse transcript, initiated on RNA isolated from 
E .coli cells containing plasmid pFF710, is visible in 
Lane R. This band migrates to the A residue at position 
77 of the SPPl sequence.
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strongly homologous to the conserved regions of E .coli and 
B .subtilis promoters. The -35 region contained the highly 
conserved bases TGG as well as the C at position 5, and the 
-10 region possessed 5 out of 6 bases homologous to the 
consensus sequence. The 17bp spacing of these regions and 
the presence of an A-T rich region (25 out of 28 bases are 
A or T) preceding the -35 region is also highly typical of 
promoter regions. The figure also shows the position of 
sequences homologous to ribosome binding sites of E .coli. 
Both potential ribosome binding sites on the fragment are 
highlighted by this analysis as would be expected of 
ribosome binding sites functional in B .subtilis, the first 
site closely following the potential promoter site.
Transcription reverse run-off experiments were 
conducted using one of the primers previously used in the 
sequencing of the SPPl fragment and were co-electrophoresed 
with a sequence ladder also generated by this primer. This 
was first carried out on mRNA isolated from E .coli. The 
result of this analysis (shown in Figure 28) is that a 
single major band is generated which migrates to position 77 
of the sequence, the predicted initiation point of 
transcription. This analysis was then extended to mRNA 
isolated from B .subtilis. As shown in Figure 29 the major 
product of reverse transcription also migrates to this 
position. Additional bands can be seen higher in the 
sequence. If these are genuine reverse transcripts they must 
originate from the unsequenced region of the SPPl fragment 
and their significance cannot be fully determined at 
present.
5.1.6 Translation from the SPPl fragment
To examine the nature of any peptides synthesised 
from the transcript, the 499 bp fragment was subjected to 
transcription and translation in. vitro using an S30 extract 
of E .coli. As shown in Figure 30 one peptide at least is
dr
L
I
Figure 29. Initiation point of transcription by 
B.subtilis RNA polymerase from the SPPl promoter.
Sequence lanes as indicated are in the order A.G.C.T. 
Lane E; reverse transcripts initiated on RNA isolated 
from E .coli cells containing plasmid pFF710. Lane B; 
reverse transcripts initiated on RNA isolated from 
B .subtilis containing plasmid pFF71. Reverse 
transcription in both cases and DNA sequence, primed 
using sequencing primer 3 on the bottom strand (shown 
in Figure 22). The major band in lane B can be seen 
migrating at position 77 of the sequence, along with 
the major band in lane E.
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Figure 30. Transcription and translation in vitro of 
plasmids pFF740, pFF700, pFF730 and the 499bp fragment of 
SPPl.
Electrophoresis on a 12.5% poly-acrylamide gel, of 
35 S-methionine labelled proteins, synthesised m  vitro
from plasmid DNA, using an S30 extract of E .coli
(Arnersham). In each case, lug of plasmid DNA was used,
except for lane F which contained lOOng of purified
fragment. Lane A; control lane containing no DNA. Lane B;
control lane containing pATl53 DNA. Lane C; plasmid
pFF740. Lane D; plasmid pFF700. Lane E; plasmid pFF730.
Lane F; PvulI to Eco RI fragment of SPPl. Arrows (a and
b), indicate two proteins identified in lane F, which are
14not present in the control lane A. Lanes G and H; C 
labelled m.wt. marker proteins. Sizes as indicated at the 
right of the figure.
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synthesised from this fragment. Plasmids pFF740 (laneC) and 
pFF700 (lane D) are identical except for the presence in the 
latter of the 499bp Pvu II to Eco RI fragment (data shown 
below). Lane D clearly shows a strong additional band 
indicative of a peptide of approximate m.wt. 6000 Dal. The 
first open frame of the fragment would generate a peptide of 
m.wt. 6300 Dal. The peptide is also synthesised from pFF730 
(lane E) which is identical,to pFF700 except for the 
presence of the synthetic ribosome binding site R.B.S. II. 
The increased intensity of the band in lane E may indicate 
synthesis of p-urogastrone (m.wt. 6.2kDal) co-migrating with 
the phage peptide. The purified fragment (lane F- ) also 
directs the synthesis of the additional peptide seen in Lane 
3. This appears to be migrating slightly more slowly, 
possibly due to the widely differing levels of protein 
present. Although some contaminating bands are present in 
lane F comparison with the blank (lane A) shows that a 
further slightly larger band is also present in lane F , 
possibly corresponding to the 78 codon second open reading 
frame. The potential encoded peptide would have a m.wt. of
8.4 kD which is in agreement with the second band observed. 
This peptide appears to be expressed at lower levels in 
vitro than the smaller peptide. Since the stop codon of the 
first open frame overlaps the Shine-Dalgarno region of the 
second, this may be due to inefficient coupling of the 
translation of the two peptides by the cell extract.
5.1.7 Discussion
It is clear that transcription initiates both in 
E .coli and in B .subtilis at the adenosine at position 77 of 
the SPPl sequence. This precedes the first putative ribosome 
binding site within the fragment thereby further indicating 
that the first open frame does encode a peptide. Although 
B .subtilis promoter regions are known to function in E .coli, 
this is the first illustration that the precise position of 
initiation is identical in both organisms. Additional
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reverse transcripts appear in lane E of Figure 29 which are 
absent in Figure 28. Since the same mRNA was used in both 
cases this probably represents RNA degradation during 
storage.
The sequence of the transcript running towards the 
Eco RI site was searched by computer for the presence of any 
inverted repeats. These sequences are often capable of 
forming stable stem-loop structures characteristic of 
transcription terminators in E.coli and B .subtilis. No 
obviously stable structure was detected and it is presumed 
that this transcript does not terminate before the Eco RI 
site.
A minimum of one peptide is synthesised from the 
phage fragment and possibly the N-terminus of a second. This 
is in agreement with recently published data (76) in which 
minicells of E .coli were shown to express two peptides from 
the 1.4 kb SPPl fragment. The smaller of these is a peptide 
of approximate m.wt. 6.3 kDal and the larger is a peptide of 
about 9.4 kDal m.wt. The larger peptide if encoded by the 
second open frame shown in this work would extend an 
additional 8 codons into the sequence of pBR322 generating a 
peptide of approximate m.wt. 9.3 kDal. This is therefore 
also in agreement.
However the data of the other authors (Tailor et a l ) 
is in considerable disagreement with these results 
concerning the DNA sequence of the 499bp fragment, over 
which 16 differences exist of which 10 are frameshifts and 6 
are substitutions. All but one of the substitutions and 3 
single base frameshifts occur in the sequence of the small 
peptide in which there are three amino acid substitutions 
and one amino acid deletion. There is in addition one silent 
mutation which appears to be part of a two base 
transversion. These variations are highlighted in Figure 25.
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it is highly unlikely that these changes in sequence 
represent allelic variation since seven of the eight DNA 
sequence differences within the region encoding the small 
peptide contribute to amino-acid variations. Allelic 
variants would be much more likely to include a greater 
number of silent mutations. Furthermore the amino-acid 
replacements are not at all conservative since in one 
instance a glycine is replaced by an arginine two residues 
distant from a deleted aspartate and in another instance a 
cysteine replaces a valine. It is equally unlikely that the 
sequence determination in this work is in error since the 
entire sequence of the region has been determined on both 
DNA strands with only two stretches of 6 bases over which 
sequence could not be determined unambiguously on both 
strands. In both of these regions the sequence could however 
be determined completely unambiguously on one strand and 
neither region is in disagreement with the other authors.
The second open reading frame detected in this work is not 
found by the other authors since frameshift mutations cause 
it to be terminated after only 13 codons. They attribute the
9.4 kDal protein to an unknown open frame upstream of the 
Pvu II site. If the sequence of Tailor £t al is correct it 
appears highly coincidental that a protein of the 
appropriate molecular weight to arise from the open frame 
detected in this work is also found by the other authors. It 
is also highly coincidental that.the open frame is preceded 
by a ribosome binding site typical of those recognised by 
B .subtilis. The DNA sequence determination carried out by 
these authors was obtained by the Maxam and Gilbert method 
(99) which I have found to be less reliable and reproducible 
than the dideoxy chain termination method used in this work. 
The data presentation on the paper is also incorrect, having 
assigned a valine residue to a TGT cysteine codon. For these 
reasons I believe their to be incorrect. Tailor et aJL also
data
Figure 31. Isolation of the (3-urogastrone gene and the
first synthetic ribosome binding site from pFF501.
Electrophoresis on a 5% poly-acrylamide gel of the 
3-urogastrone gene plus ribosome binding site I, cleaved 
from plasmid pFF501. Lanes 1 and 2; pFF501 cleaved with 
Bam HI and partially with Eco RI. Lane 3; m.wt. markers 
<)>X174 rf cleaved by Hae III. Both lanes 1 and 2 show the 
186bp fragment (A), of the gene plus the ribosome binding
site, and the 163bp fragment of the gene alone (B).
Fragment A migrates slightly below the 194bp marker band 
as expected. Lane 1 represents 1/3 of complete cleavage 
by Eco RI and lane 2 represents 1/2 of complete cleavage. 
The two high m.wt. plasmid fragments can be seen at the
top of lanes 1 and 2.
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propose the transcription initiation point to be that 
identified in this work although no data is shown to 
accurately determine this fact.
5.2 Construction of the expression plasmids
All the vectors involved in the expression of the 
{3-urogastrone gene in B . subtilis were derived initially from 
pFF2 allowing all plasmid manipulations to be carried out in 
E.coli. The plasmids although complex in initial 
construction were designed where possible to simplify 
technical manipulation and facilitate replacement of the 
promoter and ribosome binding sites. Figure 21 summarises 
the steps in the derivation of the first expression vector 
pFF710.
As shown, the ribosome binding site for translation 
of mature |3-Urogastrone was inserted using a synthetic 
linker ligated to the blunted Tag I site of 221-URO. Since 
the linker possessed an upstream Eco RI site, the synthetic 
ribosome binding site and initiator ATG could be 
subsequently removed on a 23 bp Eco RI fragment and replaced 
by an alternative sequence. The 0-urogastrone gene preceded 
by the ribosome binding site was ligated with pFF401 to form 
pFF710. This involved isolation of the Bam HI to partial Eco 
RI fragment of pFF501. This was extracted from a 5% 
polyacrylamide gel as illustrated in Figure 31. A linker 
region incorporating the remaining sequence of pATl53 on the 
Bam HI to Pst I fragment was also included to generate a 
full length copy of the plasmid. Prior to transformation of 
B .subtilis this expression vector was cleaved with Bam HI 
and the larger fragment isolated and ligated. This removed 
all pATl53 sequences and generated a large number of 
oligomeric molecules enabling efficient transformation of 
competent Bacillus subtilis. Following transformation of
1 2 3 4 5 6
Figure 32. Structural stability of plasmid pFF71.
Electrophoresis on a 1% agarose gel of pFF71 plasmid DNA 
isolated from 3G18. Lanes 1-4; plasmid DNA isolated from 
cells in shaking culture, having undergone 10 (Lane 1),
20 (lane 2), 50 (lane 3) and 100 (lane 4) cell divisions 
following inoculation by a single kanamycin (5ug/ml) 
resistant colony. Plasmid in each case is shown following 
restriction by Pvu II and Xba I. Lane 5; pFF710 plasmid 
DNA isolated from HB101 and restricted by Pvu II and Xba 
I as a control. Lane 6; m.wt. markers <j>Xl74 rf cleaved by 
Hae III.
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3G18 with plasmid pFF71 and re-streaking, plasmid integrity 
was verified by restriction analysis. Although exhaustive 
stability studies were not possible in the course of this 
work plasmid samples were prepared following growth of the 
transformed cells selected on kanamycin (5ug/ml). After 
approximately 10, 20, 50 and 100 generations including 
successive dilution into fresh medium no structural 
rearrangement of plasmid DNA was evident. This is shown in 
Figure 32. Plasmid DNA was cleaved with Xba I and Pvu II.
Two fragments of approximately 600bp are generated from the 
sites within the SPPl fragment and within the (3-urogastrone 
gene. These can also be seen in the digest of pFF710. A 
small band of roughly 340bp is also generated in pFF71 from 
the Pvu II site of pUBllO to the Xba I site of 
|3-urogastrone. This does not arise in pFF710 due to the 
presence of pATl53. The large fragment of pFF71 is 
approximately 3.65kb. The bands of approximately 900bp and 
4.25kb in lanes 1-4 are due to partial Xba I cleavage. 
Plasmid pFF710 also shows bands of roughly 3.65kb (as pFF71) 
and 4.0kb (due to pATl53 plus the small fragment of pUBllO 
and part of 0-urogastrone).
The other vectors used in this work were then 
generated from pFF710, transformed into E.coli and 
B .subtilis and plasmid integrity verified by restriction 
analysis. The steps involved in the construction of these 
vectors is shown below and restriction analysis shown in 
Figure 33.
pFF 730:
The Eco RI site within the pATl53 replicon of pFF710 
was subsequently removed by replacement of the small Pst I 
to Bam HI fragment with that of a pATl53 derivative pFFl53D, 
in which the Eco RI site had been destroyed by treatment 
with Si nuclease. The 23 bp Eco RI fragment of pFF710 was
1 2 3 4  5 6  7 8 9
Bam HI Pvu II Pvu II Bam HI Bam HI
pFF700 |-------- 1------------------- 1---------- |---------------- I 8. 8kb
250bp 4.25kb 654bp 3658bp
Bam HI Pvu II Pvu II Bam HI Bam HI
pFF710 |-------- 1------------------- 1---------- |---------------- I 8.8kb
250bp 4.25kb 677bp 3658bp
Bam HI Pvu II Pvu II Bam HI Bam HI
pFF730 |---------  1---------- |---------------- | 8. 8kb
250bp 4.25kb 676bp 3658bp
Bam HI Pvu II Xba I Eco RI Bam HI Bam HI
pFF740 |------ = T -----------1--------1------1---------------- I 8 -3kb
250bp 3.65kb 0.6kb 163bp 3658bp
Figure 33. Restriction analysis of the expression 
vectors used in B.subtilis.
Electrophoresis on 1% agarose, following excision of the 
SPPl and 0-urogastrone region from plasmids, pFF700 (Lane 
1), pFF710 (Lane 2), pFF730 (Lane 3). Cleavage in each 
case was by Pvu II and Bam HI. Lane 4, cleavage of pFF740 
by Eco RI and Xba I. Expected fragments shown below. Lane 
5, m.wt. markers (see appendix 2). Lanes 6-9; cleavage by 
Hinc II of plasmids, pFF700L (Lane 6), pFF710L (Lane 7), 
pFF730L (Lane 8), pFF740L (Lane 9). Plasmid maps shown in 
Figure 36.
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then replaced by a 22 bp fragment encoding a different 
ribosome binding site giving plasmid pFF730. Plasmids 
carrying the correctly orientated fragment were detected by 
double cleavage with enzymes Acc I and Cla I and subsequent 
electrophoresis on a 20% poly-acrylamide gel.
pFF 700:
The 23 bp Eco RI fragment of pFF710 was deleted by 
Eco RI cleavage and plasmid religation in a volume of 100 ul 
to give plasmid pFF 700. This plasmid is therefore identical 
in structure to pFF710 and pFF730 except for the deletion of 
the ribosome binding site. This provides a vector for 
subsequent insertion of ribosome binding sites and a control 
by which to measure the gene expression of the previous two 
plasmids.
pFF 740:
The SPPl promoter was deleted by cleavage with Eco RI 
and partial cleavage with Pvu II. The Eco RI site was then 
filled using the Klenow fragment of Pol I and the plasmid 
religated. Since cleavage with Pvu II leaves a blunt end 
with a 3' guanine nucleotide this then regenerated the Eco 
RI site at which position other promoters could in future be 
inserted. This plasmid was also used to demonstrate the 
absence of the SPPl peptide in Figure 30 (lane C ).
5.3 Design of the synthetic ribosome binding sites
The two synthetic ribosome binding sites, designed 
and used in this work were based upon consensus sequences 
derived from a number of chromosomally and phage encoded 
ribosome binding sites from Bacillus subtilis and related
R.B.S. I
Frame 1 Frame 2 Frame 3
* * *  * *  * * * *
GAATTCTAGGAGGCAGTCACAATG AAT TCC GAT AGC
M N S D S
R.B.S. II
Frame 2 Frame 1 Frame 3
* * * * * * ie-fck
GAATTCATAGGAGGCAATCGATG AAT TCC GAT AGC—  TAA
M N S D S
Figure 34. Termination codons within the synthetic 
ribosome binding sites.
Termination points for peptides initiating within the 
SPPl fragment are shown for each possible reading frame.
A peptide reading through R.B.S. II in frame 3 would 
terminate at the end of the f3-urogastrone gene. All other 
frames terminate within or close to the synthetic 
ribosome binding sites.
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gram-positive organisms. Primarily, they included the highly 
conserved Shine-Dalgarno (S.D.) region (5' GGAGG 3') 
situated between 5 and 12 nucleotides upstream of the ATG 
initiation codon on mRNA species of B .subtilis. Since these 
expression vectors were designed prior to the DNA sequencing 
of the SPPl fragment they had to take account of a likely 
open reading frame continuing from the Eco RI site. 
Termination codons were therefore introduced as shown in 
Figure _34, to minimise the possibility that the readthrough 
of a peptide would reduce the initiation efficiency. The 
sequence of the SPPl fragment later showed that frame 1 
encodes a fragment of phage peptide which will terminate at 
the S.D. box of R.B.S.l in pFF 710 and at a stop codon 
overlapping the ATG initiator codon of pFF 730. Computer 
search of the resulting sequence in both expression vectors 
showed no obviously stable stem-loop secondary structure in 
this region. The synthetic oligomers were flanked by the 
appropriate restriction sites necessary in the construction 
and the second site alone included a Cla I cleavage site to 
ease identification of correctly cloned and orientated 
molecules prior to DNA sequencing. The synthetic fragments 
and resulting ribosome binding sites within the expression 
vectors are illustrated in Figure 35.
In order to fully evaluate the effect on 
translational efficiency of variations in factors such as 
the degree of S.D. box complementarity and the number and 
nature of the bases between this region and the ATG codon, a 
large number of different ribosome binding sites would need 
to be tested. To begin this sort of analysis, the second 
site used in this work was designed to show a greater degree 
of complementarity to the 16S rRNA subunit and the length of 
the spacer region used was more typical of those found on 
native mRNA molecules of B.subtilis. It might therefore be 
expected to initiate translation more efficiently. The 
effect of these differences were evaluated both in
R.B.S. I
R.B.S. II
5' AATTCTAGGAGGCAGTC 3' 
3' GATCCTCCGTCAG 51
AATTCATAGGAGGCAATCGATG
GTATCCTCCGTTAGCTACTTAA
pFF700 V L R D E F R * * *
GTT CTT CGG GAC GAA TTC CGA TAG CGA GTG TCC TCT GAG TCA
pFF710 V L R D E F * * *
GTT CTT CGG GAC GAA TTC TAG GAG GCA GTC ACA ATG AAT TCC
* *** * M N S
R.B.S. I
pFF730 V L R D E F I G G N R  ***
GTT CTT CGG GAC GAA TTC ATA GGA GGC AAT CGA TGA ATT CGA
*** * * M N S
R.B.S. II
Complementarity to the 16S rRNA 3' end:
E . c o l i   3' ATTCCTCCAC
******
RBS 1 AATTCTAGGAGGCAGTCACA ATG
* * * * * *
RBS 2 AATTCATAGGAGGCAATCG ATG
B .subtilis 3' TCTTTCCTCCAC
* * * * * *
RBS 1 AATTCTAGGAGGCAGTCACA ATG
* * * * * * *
RBS 2 AATTCATAGGAGGCAATCG ATG
Figure 35. The synthetic ribosome binding sites.
The DNA sequence of the oligomers comprising the two 
synthetic ribosome binding sites is given at the top of 
the figure. The resulting ribosome binding sites within 
the expression plasmids are shown below. The highly 
conserved Shine-Dalgarno regions are indicated by 
asterisks below the DNA sequence in the case of plasmids 
pFF710 and pFF730. The N-terminal amino acid sequence of 
3-urogastrone is also shown below the DNA sequence of 
these plasmids. The C-terminal residues of the putative 
SPPl peptide in each case is shown above the DNA 
sequence. Termination codons are indicated by asterisks 
above the DNA sequence. Complementarity of the 
Shine-Dalgarno regions to the 3' end of the 16S rRNA in 
each host is shown at the bottom.
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B .subtilis and also in E .coli which displays a far lesser 
stringency of sequences which can act as effective ribosome 
binding sites. Both of the synthetic sites could therefore 
be reasonably expected to function effectively in E .coli in 
which it seemed likely that differences in translational 
efficiency would be less pronounced than in Bacillus 
subtilis.
5.4 Expression of 0-urogastrone in E.coli and B.subtilis
Cell extracts were prepared from cultures of HB101 
alone and HB101 containing plasmids pFF710, pFF730, pFF700 
and pFF740. Each was then examined for the presence of 
0-urogastrone by radio-immuno assay as described in Chapter 
2. Similarly, extracts from cultures of 3G18 alone and 3G18 
carrying plasmids pFF71, pFF73, pFF70 and pFF74, were 
prepared and assayed for 0-urogastrone activity. The results 
(summarised in Table 3) were extremely inconclusive. No 
0-urogastrone activity was detected in any samples of either 
host in the absence of plasmid or in the presence of 
plasmids pFF700, pFF70, pFF740 or pFF74. However the levels 
of 0-urogastrone detected in the other strains was extremely 
variable throughout the growth range of the cells over which 
samples were taken (A^qq 0.3-1.0). The levels of 
0-urogastrone varied between 30-200 ng/ml of cells 
(corrected to an A^qq of 1.0) in E .coli and between 30-150 
ng/ml of cells (corrected) in B .subtilis. No pattern was 
evident and no consistent correlation possible between 
levels detected in cells expressing 0-urogastrone from 
R.B.S. I or R.B.S. II. From these results the only 
conclusion possible is that 0-urogastrone is synthesised 
using the SPPl promoter and either synthetic ribosome 
binding site in both E .coli and B .subtilis. The levels are 
not significantly different between hosts, nor are they 
significantly different from the levels of 0-urogastrone
Table 3
Cell Sample ng/uro ml to Aeoo M
HB 101 B.R.
HB 101+pFF 7A-0 BR.
HB 101+pFF700 B.R.
HB101+pFF710 30-20 0
HB 101+pFF 730 30-200
3G18 B.R.
3G18*pFF70 B.R.
3G18+pFF7C B.R.
3G18+pFF71 30-150
3G18+pFF73 30-150
Table 3. Expression of g-urogastrone in HB101 and 3G18 
using the SPPl promoter and the synthetic ribosome
binding sites.
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detected in cells expressing the native peptide under 
control of the trp promoter (described in Chapter 3).
Clearly the system designed for gene expression in 
B .subtilis was functional but accurate evaluation of the 
translational efficiency of the synthetic ribosome binding 
sites required a more consistent level of a detectable 
peptide to be present.
In an attempt to provide a faster and more simple 
means to assay gene expression the 0-urogastrone gene was 
then fused to a fragment of the lac Z gene of E .coli 
generating a peptide fusion. This allows rapid and accurate 
detection of 0-galactosidase using a simple assay or X-gal 
indicator medium and has been widely applied in the study of 
gene expression in heterologous systems. In addition, it had 
emerged from the further studies on the expression of the 
0-urogastrone gene using the trp expression vectors that the 
mature peptide had a much shorter half-life (2mins) than the 
Trp-E fused molecule (5 mins). Since the fragment of the Trp 
E peptide appeared to somehow stabilise the molecule in 
E .coli it seemed that fusion to 0-galactosidase might have a 
similar effect and may therefore be a more sensitive and 
accurate measure of the expression efficiency of the shuttle 
vectors. Since much larger protein fusions to 
0-galactosidase have been previously used (100) it was 
likely that the enzyme would retain activity with an 
N-terminal fragment of 0-urogastrone.
o
pMCl40 3
Bam HI Aha III
— i----------------------------     1--------
 ____________________________________  i__
lacZ lacY
(3-urogastrone lacZ ^  (pFF 710R)
Bgl II Bam HI Aha III Nru I
TAT CGA GAT C C C ------ //---TTT CGA---------
ATA GCT CTA G G G ------ //---AAA GCT--------
pUBllO SPPl gene fusion pATl53 pUBllO
pFF700L
pFF710L
pFF730L |
1 — .. 1“ -
3.0kb
“  1 —  --------  “ ---- 1.......... -"I......
Positions of Hinc II cleavage.
665bp 624bp 1828bp 2230bp 2.33kb
- 1 
0.5kb
i ii r i 
*->
i i 1--- 1
3.0kb 688bp 624bp 1828bp 
1 I 1
2230bp 2.33kb
1 i
0.5kb
1 1 1 
*->
1 I 1 1 1
3.0kb 687bp 624bp 1828bp
1 i i
2230bp 2.33kb
1 *
0.5kl
i i1 1 1 
*->
1 1--- 1 — 1
3.19kb 624bp 1828bp
I l —  I. ,
2230bp 2.33kb 0.
_ i________  _i__
.5kb
PFF740L |-------------- 1-----1---------1----------1---- 1----- 1 10.7kb
Figure 36. Generation of plasmid pFF710L.
The 3122bp, Bam HI to Aha III fragment of the lacZ gene
from pMCl403, was inserted into plasmid pFF710R as shown 
at the top of the figure. The resulting plasmid pFF710L 
and derivatives, pFF730L, pFF700L and pFF740L are 
illustrated below with expected Hinc II cleavage 
fragments indicated. The position of the SPPl promoter is 
also indicated (*->). The result of Hinc II cleavage of
each plasmid is shown in Figure 33.
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5.5 lacZ fusion peptides
A fragment encompassing almost all of the lacZ gene 
was excised from plasmid pMCl403 on a 3kb fragment as shown 
in Figure 36. The Bam HI site was ligated to the Bgl II site 
within the 0-urogastrone gene fusing the two peptides in the 
correct reading frame. For the purpose of this construction 
a derivative of pFF710 was used in which the pATl53 sequence 
is in the reverse orientation. The Aha III site within the 
first few residues of the lac Y gene was ligated to the Nru 
I site within pATl53 since both enzymes generate blunt ends 
upon cleavage. The resultant fusion named pFF710L thereby 
included very little extraneous sequence. The small Xba I 
fragment from each of vectors pFF730, pFF 700, and pFF 740 
was cloned into Xba I cleaved pFF710L to generate lacZ 
fusion equivalents of each of the vectors used to study 
native 0-urogastrone expression. Since these vectors do not 
carry an easily excisable pAT 153 replicon this was not 
removed prior to transformation of B .subtilis. Oligomers 
were instead generated by cleavage at the unique Bgl II site 
within the kanamycin resistance gene of pUBllO.
Since the host E.coli strain used has a deletion of 
the entire chromosomal lacZ gene and B .subtilis strain 3G18 
possesses no 0-galactosidase activity, all enzyme activity 
is derived from the plasmid borne fusions. Colonies of HB101 
carrying plasmids pFF710 and pFF730 turned blue on X-gal 
indicator medium, as did 3G18 carrying plasmids pFF71 and 
pFF73. Relative blueness could not accurately be determined 
although in each host the presence of R.B.S. II led to a 
greater degree of blue colour. In HB101 the presence of 
plasmid pFF700 caused the development of a pale blue colour 
over 2-3 days indicating very low levels of 0-galactosidase 
present. This must be due to fortuitous translational 
initiation on transcripts originating from the SPPl 
promoter.
Graph 3. ExpresaLon of urogoatrone/B-got fusion Ln HH87 from R.B.5. I and R.B.5. II
4- pFF700L/HH87 
O  pFF710L/HH87 
O  pFF730L/HW87
A  pFF700L 
•  pFF7lOL 
■  pFF730L
O 275
§(T 250
225
200
a  125
(mlnJ
Table 4
Sample 1 2 3 4 5 6
Time 0 15 45 75 135 195
i
pFF700L 0-35 0-5 0-74 1-06 1-5 1 62
pFF710L 0-3 0-A6 0-67 0-98 1-48 1-6
PFF730L 0-3 0-45 0 65 098 1-47 1-63
o
_^o
"o
cn
Si
PFF700L 236 185 330 716 848 713
pFF710L 5287 6488 8485 11460 19760 23130
pFF730L 11138 14097 20520 24090 25910 23524
Graph 3. and Table 4. Expression in HW87 of 
urogastrone/fi-galactosidase fusion peptide.
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5.6 Expression of urogastrone-Galactosidase peptide
The 0-Galactosidase activity in both hosts carrying 
each of the four plasmids was now accurately determined by 
spectrophotometric assay and is shown in Tables 4 and 5. No 
0-galactosidase activity was detected as expected in either 
HW87 or 3G18 when no plasmid was present. Similarly in HW87 
carrying plasmid pFF740L no activity was detected throughout 
the growth of the cells (A^qq 0.3-1.4). However very low 
levels of activity were detected in HW87 carrying plasmid 
pFF700L and quite substantial levels were expressed from 
pFF710L and pFF730L. In 3G18 no 0-galactosidase activity was 
detected throughout the growth of the cells carrying pFF70
or pFF74 (Agoo 0.3-1.5) but low levels were detected in the
presence of pFF71 and pFF73. The relative levels of enzyme 
were corrected for protein concentration in cell extracts 
and normalised to A^qq 1.0 to allow comparison. Time courses 
of expression for each host/plasmid combination remained 
consistent over repeat experiments showing both in E .coli 
and B .subtilis a roughly twofold higher level of 
0-galactosidase activity in cells expressing lacZ fused 
urogastrone from R.B.S. II than R.B.S. I. This is
illustrated in Graphs _3 and 4.
Copy numbers of plasmids from E.coli were estimated 
by densitometric scanning of plasmid extracts on 1% agarose 
gels, showing all four plasmids to have copy numbers of 
approximately 50. Although accurate copy number 
determinations could not be carried out in B .subtilis due to 
frequently observed inconsistency of plasmid DNA isolation 
it is unlikely that the structural differences of these 
plasmids, especially the minor differences between pFF71 and 
pFF73 would bring about significant differences in copy 
number. Extensive plasmid stability studies were not carried
Graph i^_ExppB«gLon g/_Mcggqatrgnq/@-_ggl fualon In 3618 from R.B.S, I and R.B.S. II.
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Table 5
Sample 1 2 3 4 5 6
Time 0 15 30 60 90 120
o
o
\o
<
pFF 710L 0-3 0-42 0-6 107 1-44 1 56
pFF 730L 0-3 0-46 0 63 105 1 39 1-58
o
o pFF710L 320 245 250 376 1735 1685
pFF 730L 778 594 469 1281 5124 4800
Graph 4. and Table 5. Expression in 3G18 of 
urogastrone/g-galactosidase fusion peptide.
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out although plating on X-gal indicator medium following 
growth of all initially blue host/plasmid combinations 
showed no evidence of segregants reduced in blue colour.
5.7 Discussion
These results demonstrate that both synthetic 
ribosome binding sites are capable of initiating translation 
in B .subtilis and in E .coli. This supports the data on the 
expression of p-urogastrone. However, these results also 
show that higher |3-galactosidase activities are observed 
when using R.B.S. II rather than R.B.S. I. Although 
additional data is required to exclude the possibility that 
the difference is due to variations in levels of synthesis 
or breakdown of mRNA, the more likely explanation is that 
the two ribosome binding sites have differing efficiencies 
of translational initiation. This could be due to subtle 
alterations in mRNA secondary structure or to the effect of 
the changes in the S.D. region affecting the interaction 
with 16S rRNA. No significant secondary structure was 
observed by computer search of the region around either 
ribosome binding site but it is interesting to note that 
R.B.S. II does display increased homology to the 3' end of 
the 16S rRNA than R.B.S. I. In addition, translation from 
the open frame preceding the synthetic ribosome binding 
sites would be likely to influence the efficiency of 
translation. Although constraints of time and technical 
difficulties precluded accurate determinations of mRNA 
levels of the strains used in this work, the results do show 
that small sequence variations in synthetic ribosome binding 
sites can lead to large differences in observed protein 
levels in both organisms. The much lower enzyme activities 
obtained in B .subtilis may reflect the differing stringency 
of gene expression of the organisms or higher levels of 
proteolysis. It must be emphasised that these studies are
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preliminary and represent only the beginning of the 
development of a suitable system for gene expression in 
B .subtilis. Both proteins used are to differing degrees 
foreign to both organisms. Ideally a native bacillus 
protein, or an E .coli protein showing high conservation of 
structure and function with B .subtilis would be more 
appropriate in studies of gene expression. Furthermore, the 
study by specific mutation of a known region of 
translational initiation in B .subtilis would allow a more 
controlled evaluation of the influence of minor sequence 
variation. The extension of the concepts examined in this 
work and the further development of this system to examine 
these possibilities are now considered.
CHAPTER 6
GENERAL DISCUSSION 
AND
CONCLUSIONS
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It is quite clear that the cloning in E .coli and 
expression of 0-urogastrone demonstrated in these results, 
illustrates the value of total gene synthesis in achieving 
bacterial expression of a eukaryotic peptide. Very large 
quantities of human urine were previously required to obtain 
similar quantities of 0-urogastrone to that detected in 
these preliminary expression studies. In addition the 
subsequent increases in bacterial expression levels have 
yielded much higher quantities of the peptide than could 
have otherwise been realistically obtained. Similar 
observations have of course been made upon the expression in 
bacteria of other human genes derived from natural sources.
In this respect it is important to stress that many of the 
significant advantages evident in the application of 
sophisticated technology allowing peptide expression from a 
synthetic gene are largely practical. This is very important 
since technical difficulties can often be severely limiting 
in instances where theoretical knowledge is not , a fact 
exemplified by the problems discussed in the isolation of 
human mRNA and that of 0-urogastrone in particular. It is 
also illustrated in the necessity for careful consideration 
of many aspects in the design of the gene. The value of the 
logic applied to the gene assembly, permiting relatively 
trouble free isolation of the full sequence and of 
restricion cleavage and gel purification were clear. These 
factors can largely influence the value of this approach as 
a faster and more feasible alternative to cDNA or chromosomal 
gene cloning. The benefit of many of the other factors 
included in the gene design can only be evaluated after 
extensive studies on the expression of the gene. For example 
the inclusion of the facility for peptide fusions did allow 
more accurate assessment of gene expression but also showed 
interesting differences in the protease sensitivity of the 
native and Trp E fused 0-urogastrone molecules. This 
illustrates the point that perhaps the greatest value of 
this work lies not neccesarily in the demonstration of
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expression of the synthetic gene but in the facility to 
easily modify the peptide itself or the expression system. 
This has already potentiated many studies arising from 
observations made upon 0-urogastrone expression.
Programmes of work are currently investigating the 
different susceptibilities of the native and Trp E fused 
molecules to proteolytic degradation in E.coli. Expression 
of 0-urogastrone has been used to evaluate expression from 
plasmids containing tandemly repeated trp promoters and from 
plasmids carrying mutations in copy number regulation. In 
addition modifications have been made to the N-terminal 
linker region to leave only a single lysine residue. This 
follows observations of incompletely cleaved protein 
following treatment with trypsin. Modifications have also 
been made to the C-terminal region to incorporate a stretch 
of arginine residues. This has allowed the development of a 
novel technique of peptide purification (101). Since the 
C-terminal residue of native 0-urogastrone is an arginine 
residue both the N-terminal and C-terminal peptides can be 
removed by trypsin digestion. The combination of these 
developments has enabled the isolation from E.coli, and 
purification to homogeneity of a several hundred 
milli-grammes of 0-urogastrone. This has enabled current 
investigations into the crystallisation and the 
determination of the 3-D structure of the molecule and the 
commencement of extensive clinical trials to examine its 
medical potential.
The examination of the expression of 0-urogastrone in 
B.subtilis did not show significant differences in maximal 
levels of the peptide detected by radio-immuno assay from 
that detected in E .coli. Although the apparent levels of 
peptide present were lower, the inconsistency of the results 
allow no realistic evaluation of gene expression. It is 
highly likely that rapid proteolysis of the peptide occurs
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in B .subtilis as has now been shown in E.coli. Furthermore, 
the high levels of 0-urogastrone which have now been 
purified from E .coli have removed the immediate necessity 
for the use of an alternative host organism as a source of 
the peptide. It is therefore important to distinguish at 
this point the two aspects of the study of 0-urogastrone 
expression in B.subtilis. Although an initial evaluation of 
the levels of the peptide were desired in the consideration 
B .subtilis as a suitable alternative host, the synthetic 
gene was used also in the study of regulatory aspects of 
gene expression. The use of 0-galactosidase fusions to 
permit a more accurate and reproducible evaluation of 
expression, illustrates that a gene of prokaryote origin 
would have been more appropriate for this latter purpose. A 
peptide native to B .subtilis or possibly an E .coli peptide 
would have been more likely to be resistant to intracellular 
proteolysis therby introducing fewer variables to the 
examination. Had an appropriate gene been available at the 
time, a more controlled assessment of the function of 
synthetic ribosome binding sites could have been undertaken. 
In addition constraints upon time did not permit the full 
characteristion of the promoter region prior to the design 
of these expression systems. This neccessitated the 
inclusion of termination codons within the synthetic 
ribosome binding sites which led to variations in the 
termination points of the second open reading frame of the 
phage fragment. Nevertheless, several aspects of this study 
do indicate the worth of the development of this system. The 
SPPl promoter used has previously been shown to be a very 
efficient promoter and is likely to be very effective in the 
expression of heterologous genes. It is likely that the 52 
residue peptide is efficiently expressed in B.subtilis.
Since the exact point of transcription initiation is now 
known this promoter could form the basis of a more useful 
expression system. It is also clear that synthetic ribosome 
binding sites can be used in the initiation of translation
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in B .subtilis. Although it is not possible to determine the 
reason for the differences in observed expression the design 
of these regions can clearly influence the efficiency of 
translation. Therefore a more controlled system based upon 
these results may be very effective in B .subtilis. To pursue 
this possibility two separate alterations have been made to 
the SPPl fragment by site directed mutagenesis which should 
allow the expression of alternative genes. Transcription 
would again be under control of this promoter and 
translation initiated from the ribosome binding site of the 
small phage peptide. The structure of these variants are 
illustrated in appendix 1. They have been designed to 
introduce specific restriction enzyme sites at the 
initiation region of the small phage peptide allowing 
alternative genes to be inserted and expression examined 
using modified versions of the native regulatory region of 
the phage. The restriction sites introduced (Eco RI and Bam 
HI) have been chosen for the particular inclusion of two 
genes now available which should allow more effective 
analysis of the effect of minor changes in promoter and 
ribosome binding site. These are: i) the aspC gene of E .coli 
K12, encoding the aspartate aminotrasferase (AAT). This has 
been recently cloned in this laboratory (103), and ii) 
exonuclease II of Staphylococcus aureus (J-I. Flock personal 
communication). These genes contain the appropriate 
restriction sites for combination with the SPPl variants.
The aspartate aminotransferase can be over-expressed 
one-hundred fold in E .coli without significant proteolytic 
degradation and the exonuclease can similarly be expressed 
to very high levels in S .aureus. The vectors used for gene 
expression in B .subtilis in this work were clearly 
functional to a degree. The study of more appropriate 
subject peptides should be more useful in the development of 
an expression system. In this event the eventual
-97-
introduction of the 0-urogastrone gene at this Eco RI site 
would remain a possibility and the expression of the peptide 
in B .subtilis could yet represent a viable option.
(I
( <
Wild type:
AGAGAGGGGGGGACAAC ATG AAC GAG CAA AAG AGA
* * * * *
AGAGAGGAGGTGACAAC ATG AAT TCG CAA AAG AGA
Mutant:
• •
Appendix 1. Figure 1. Modification to the SPPl fragment 
by site-directed mutagenesis.
Track 1; Wild type sequence of SPPl DNA. Track 2;
Sequence of the mutation introduced to the SPPl fragment. 
Both tracks show sequence lanes as read, in the order 
A.G.C.T. Position of the sequence changes is indicated by 
brackets. The wild type and mutant sequences are 
illustrated below, with differences indicated by 
asterisks. The resulting Eco RI site of the mutant is 
unde rlined.
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APPENDIX 1
Two mutations were introduced by site-directed 
mutagenesis, within the ribosome binding site of the small 
phage peptide. These introduced cleavage sites for the 
restriction endonucleases Eco RI and Bam HI. The wild type 
sequence and that of the two mutants are shown below. The 
restriction endonuclease cleavage sites are underlined. The 
sequence begins with the first base of the mRNA. The DNA 
sequence of the wild type and mutant 1 are shown in 
Figure 1.
wild type:
ATAGAGAGGGGGGGACAAC ATG AAC GAG CAA AAG AGA 
mutant 1:
ATAGAGAGGAGGTGACAAC ATG AAT TCG CAA AAG AGA
mutant 2:
ATAGAGAGGAGGATCCAAC ATG AAC GAG CAA AAG AGA
-99-
These mutations permit the insertion of the S .aureus 
exonuclease gene (mutant 1) and the E .coli aspC gene (mutant 
2). The exonuclease gene possesses an Eco RI site at the 
N-terminus of the peptide and the aspC gene possesses a Bam 
HI site introduced by site-directed mutagenesis within the 
ribosome binding site. The sequence of the N-terminal region 
of the mutated aspC gene and the resulting SPPl derived 
expression vector are shown overleaf. The Bam HI site is 
underlined.
wild type aspC gene:
ATAATGGAACCTCGTC ATG TTT GAG
mutated aspC gene:
ATAATGGATCCTCGTC ATG TTT GAG
M F E
SPPl-aspC expression plasmid:
ATAGAGAGGAGGATCCTCGTC ATG TTT GAG
M F E
-100-
APPENDIX 2
Molecular weight markers comprising restriction 
digests of the DNA of phages X and <|>X174 generated fragments 
of sizes shown below:
X Hind III digest.
1. 23,130 bp
2. 9,419 bp
3. 6,557 bp
4. 4,371 bp
5. 2,322 bp
6. 2,028 bp
7. 564 bp
8. 125 bp
<|>X174 Hae III digest.
1. 1,353 bp
2. 1,078 bp
3. 872 bp
4. • 603 bp
5. 310 bp
6. 281 bp
7. 271 bp
8. 234 bp
9. 194 bp
10. 118 bp
11. 72 bp
-101-
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